Sequist, Lecia
eCommons Login: LVS1
first name: Lecia
last name: Sequist
coauthor of: Piotrowska, Zofia
coauthor of: Heist, Rebecca
coauthor of: Shaw, Alice
coauthor of: Gainor, Justin
coauthor of: Dagogo-Jack, Ibiayi
full name: Lecia Vandam Sequist, M.D.
has faculty rank: Full Professor
has network: selected publications
has network: research areas
has network: coauthor of
has network: similar to
latitude: 42.36239000000000
longitude: -71.06931690000000
Person ID: 28331
person in primary position: Landry Family Professor of Medicine in the Field of Medical Oncology
physical neighbor: Barbesino, Giuseppe
physical neighbor: Kopans, Daniel
physical neighbor: Passeri, Jonathan
physical neighbor: Randolph, Mark
physical neighbor: Saini, Sanjay
similar to: Shaw, Alice
similar to: Costa, Daniel
similar to: Gainor, Justin
similar to: Johnson, Bruce
similar to: Christiani, David
type: Agent
type: Person
selected publications: Authorship 1835784
selected publications: Authorship 1835786
selected publications: Authorship 1832197
selected publications: Authorship 1792186
selected publications: Authorship 1831631
selected publications: Authorship 1826042
selected publications: Authorship 1822366
selected publications: Authorship 1738685
selected publications: Authorship 1741268
selected publications: Authorship 1817967
selected publications: Authorship 1736703
selected publications: Authorship 1734422
selected publications: Authorship 1717218
selected publications: Authorship 1708017
selected publications: Authorship 1656815
selected publications: Authorship 1710272
selected publications: Authorship 1702352
selected publications: Authorship 1697645
selected publications: Authorship 1650098
selected publications: Authorship 1665652
selected publications: Authorship 1647491
selected publications: Authorship 1641038
selected publications: Authorship 1636907
selected publications: Authorship 1641599
selected publications: Authorship 1629945
selected publications: Authorship 1629947
selected publications: Authorship 1623858
selected publications: Authorship 1600546
selected publications: Authorship 1605103
selected publications: Authorship 1598788
selected publications: Authorship 1605461
selected publications: Authorship 1596674
selected publications: Authorship 1573569
selected publications: Authorship 1566934
selected publications: Authorship 1592557
selected publications: Authorship 1583259
selected publications: Authorship 1596541
selected publications: Authorship 1516955
selected publications: Authorship 1491481
selected publications: Authorship 1552402
selected publications: Authorship 1513872
selected publications: Authorship 1513874
selected publications: Authorship 1493092
selected publications: Authorship 1499479
selected publications: Authorship 1466059
selected publications: Authorship 1449468
selected publications: Authorship 1450679
selected publications: Authorship 1465054
selected publications: Authorship 1442057

eCommons Login
tag name: catalyst:eCommonsLogin
type: DatatypeProperty

coauthor of
tag name: prns:coAuthorOf
type: ObjectProperty

end date
tag name: prns:endDate
type: DatatypeProperty

Faculty Rank
type: Class

full name
tag name: prns:fullName
type: DatatypeProperty

author list
tag name: prns:hasAuthorList
type: DatatypeProperty

has faculty rank
tag name: prns:hasFacultyRank
type: ObjectProperty

has network
tag name: prns:hasNetwork
type: ObjectProperty

published in
tag name: prns:hasPublicationVenue
type: DatatypeProperty

information resource reference
tag name: prns:informationResourceReference
type: DatatypeProperty

is primary position
tag name: prns:isPrimaryPosition
type: DatatypeProperty

latitude
tag name: prns:latitude
type: DatatypeProperty

longitude
tag name: prns:longitude
type: DatatypeProperty

photo
tag name: prns:mainImage
type: ObjectProperty

maximum weight
tag name: prns:maxWeight
type: DatatypeProperty

journal title abbreviation
tag name: prns:medlineTA
type: DatatypeProperty

MeSH DescriptorUI
tag name: prns:meshDescriptorUI
type: DatatypeProperty

MeSH semantic group name
tag name: prns:meshSemanticGroupName
type: DatatypeProperty

minimum weight
tag name: prns:minWeight
type: DatatypeProperty

number of authors
tag name: prns:numberOfAuthors
type: DatatypeProperty

number of connections
tag name: prns:numberOfConnections
type: DatatypeProperty

number of publications
tag name: prns:numberOfPublications
type: DatatypeProperty

Person ID
tag name: prns:personId
type: DatatypeProperty

person in primary position
tag name: prns:personInPrimaryPosition
type: ObjectProperty

physical neighbor
tag name: prns:physicalNeighborOf
type: ObjectProperty

position in department
tag name: prns:positionInDepartment
type: ObjectProperty

position in division
tag name: prns:positionInDivision
type: ObjectProperty

predicate node
tag name: prns:predicateNode
type: ObjectProperty

principal investigator name
tag name: prns:principalInvestigatorName
type: DatatypeProperty

publication date
tag name: prns:publicationDate
type: DatatypeProperty

similar to
tag name: prns:similarTo
type: ObjectProperty

sort order
tag name: prns:sortOrder
type: DatatypeProperty

start date
tag name: prns:startDate
type: DatatypeProperty

uniqueness weight
tag name: prns:uniquenessWeight
type: DatatypeProperty

year
tag name: prns:year
type: DatatypeProperty

Academic Article
type: Class

Article
type: Class

Document
type: Class

PubMed Identifier
tag name: bibo:pmid
type: DatatypeProperty

Address
type: Class

address line 1
tag name: vivo:address1
type: DatatypeProperty

address line 2
tag name: vivo:address2
type: DatatypeProperty

address line 3
tag name: vivo:address3
type: DatatypeProperty

city
tag name: vivo:addressCity
type: DatatypeProperty
type: FunctionalProperty

postal code
tag name: vivo:addressPostalCode
type: DatatypeProperty
type: FunctionalProperty

state or province
tag name: vivo:addressState
type: DatatypeProperty
type: FunctionalProperty

selected publications
tag name: vivo:authorInAuthorship
type: ObjectProperty

author rank in publication
tag name: vivo:authorRank
type: DatatypeProperty
type: FunctionalProperty

Authorship
type: Class

Department
type: Class

Division
type: Class

Grant
type: Class

research areas
tag name: vivo:hasResearchArea
type: ObjectProperty

research activities
tag name: vivo:hasResearcherRole
type: ObjectProperty

HR job title
tag name: vivo:hrJobTitle
type: DatatypeProperty

Information Resource
type: Class

linked author
tag name: vivo:linkedAuthor
type: ObjectProperty

linked information resource
tag name: vivo:linkedInformationResource
type: ObjectProperty

mailing address
tag name: vivo:mailingAddress
type: ObjectProperty

middle name or initial
tag name: vivo:middleName
type: DatatypeProperty
type: FunctionalProperty

positions
tag name: vivo:personInPosition
type: ObjectProperty

phone
tag name: vivo:phoneNumber
type: DatatypeProperty

Position
type: Class

position in organization
tag name: vivo:positionInOrganization
type: ObjectProperty

preferred title
tag name: vivo:preferredTitle
type: DatatypeProperty
type: FunctionalProperty

Researcher Role
type: Class

researcher role of
tag name: vivo:researcherRoleOf
type: ObjectProperty

contributes to
tag name: vivo:roleContributesTo
type: ObjectProperty

sponsor award id
tag name: vivo:sponsorAwardId
type: DatatypeProperty
type: FunctionalProperty

predicate
tag name: rdf:predicate
type: ObjectProperty

type
tag name: rdf:type
type: ObjectProperty

label
tag name: rdfs:label
type: DatatypeProperty

Concept
type: Class

Agent
type: Class

first name
tag name: foaf:firstName
type: DatatypeProperty
type: FunctionalProperty

last name
tag name: foaf:lastName
type: DatatypeProperty
type: FunctionalProperty

Organization
type: Class

Person
type: Class

The Role of Liquid Biopsies in Lung Cancer Screening.
PubMed Identifier: 28734402
author list: Dagogo-Jack I, Sequist LV, Piotrowska Z
published in: Seminars in roentgenology
information resource reference: The Role of Liquid Biopsies in Lung Cancer Screening. Semin Roentgenol. 2017 Jul; 52(3):185-187.
journal title abbreviation: Semin Roentgenol
publication date: 2017-06-03T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1049516
type: Authorship
author rank in publication: 23
linked author: Sequist, Lecia
linked information resource: Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Authorship 1049511
type: Authorship
author rank in publication: 16
linked author: Sequist, Lecia
linked information resource: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.

Authorship 1046567
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
PubMed Identifier: 29496255
author list: Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ
published in: Lung cancer (Amsterdam, Netherlands)
information resource reference: Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer. 2018 03; 117:44-49.
journal title abbreviation: Lung Cancer
publication date: 2018-02-03T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.
PubMed Identifier: 29453278
author list: Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018 03 06; 115(10):2467-2472.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2018-02-16T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
PubMed Identifier: 29483136
author list: Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, Hazar-Rethinam MH, Licausi JA, Gomez-Caraballo M, Kem M, Jani KN, Azimi R, Abedpour N, Menon R, Lakis S, Heist RS, Büttner R, Haas S, Sequist LV, Shaw AT, Wong KK, Hata AN, Toner M, Maheswaran S, Haber DA, Peifer M, Dyson N, Thomas RK, Farago AF
published in: Cancer discovery
information resource reference: Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 2018 05; 8(5):600-615.
journal title abbreviation: Cancer Discov
publication date: 2018-02-26T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1054035
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
PubMed Identifier: 29570421
author list: Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, Leming P, Geese WJ, Yoon D, Li A, Brahmer J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018 06 10; 36(17):1675-1684.
journal title abbreviation: J Clin Oncol
publication date: 2018-03-23T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1055540
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

Authorship 1055183
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.
PubMed Identifier: 29580950
author list: Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Yang JC
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2018 06; 13(6):792-800.
journal title abbreviation: J Thorac Oncol
publication date: 2018-03-23T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
PubMed Identifier: 29579334
author list: Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA
published in: Cancer
information resource reference: Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer. 2018 06 01; 124(11):2407-2414.
journal title abbreviation: Cancer
publication date: 2018-03-26T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
PubMed Identifier: 18827612
author list: Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS, Lynch TJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008 Oct; 3(10):1153-8.
journal title abbreviation: J Thorac Oncol
publication date: 2008-10-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
PubMed Identifier: 18980981
author list: Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman J
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res. 2008 Nov 01; 14(21):6867-76.
journal title abbreviation: Clin Cancer Res
publication date: 2008-11-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
PubMed Identifier: 19671843
author list: Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009 Aug 15; 15(16):5267-73.
journal title abbreviation: Clin Cancer Res
publication date: 2009-08-11T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.
PubMed Identifier: 20432502
author list: Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ
published in: EMBO molecular medicine
information resource reference: Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58.
journal title abbreviation: EMBO Mol Med
publication date: 2010-05-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1057906
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
PubMed Identifier: 29653820
author list: Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K
published in: Clinical lung cancer
information resource reference: Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer. 2018 07; 19(4):e465-e479.
journal title abbreviation: Clin Lung Cancer
publication date: 2018-03-17T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
PubMed Identifier: 19701107
author list: Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009 Nov; 4(11):1389-96.
journal title abbreviation: J Thorac Oncol
publication date: 2009-11-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1060777
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.
PubMed Identifier: 29703765
author list: Khandekar MJ, Piotrowska Z, Willers H, Sequist LV
published in: The oncologist
information resource reference: Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Oncologist. 2018 09; 23(9):1054-1062.
journal title abbreviation: Oncologist
publication date: 2018-04-27T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.
PubMed Identifier: 23093251
author list: Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA
published in: Cancer discovery
information resource reference: Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012 Nov; 2(11):995-1003.
journal title abbreviation: Cancer Discov
publication date: 2012-10-23T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

HER2 amplification as a biomarker in non-small cell lung cancer
author list: Sequist, LV.
published in: Am J Oncol Rev
information resource reference: HER2 amplification as a biomarker in non-small cell lung cancer. Am J Oncol Rev. 2006; 5(3):151-153.
publication date: 2006-03-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
PubMed Identifier: 17285735
author list: Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ
published in: The oncologist
information resource reference: Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8.
journal title abbreviation: Oncologist
publication date: 2007-01-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1068623
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: The Role of Liquid Biopsies in Lung Cancer Screening.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
PubMed Identifier: 21430269
author list: Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA
published in: Science translational medicine
information resource reference: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26.
journal title abbreviation: Sci Transl Med
publication date: 2011-03-23T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1046641
PubMed Identifier: 22440336
author list: Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von Pawel J, Schwartz B, Von Roemeling R, Sandler AB
published in: Clinical lung cancer
information resource reference: Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer. 2012 Sep; 13(5):391-5.
journal title abbreviation: Clin Lung Cancer
publication date: 2012-03-21T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

Authorship 1070673
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.
PubMed Identifier: 29861396
author list: Camidge DR, Sequist LV, Jänne PA, Weickhardt AJ, Dowling ES, Alicea J, Fan J, Oxnard GR
published in: Clinical lung cancer
information resource reference: Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. Clin Lung Cancer. 2018 09; 19(5):e655-e665.
journal title abbreviation: Clin Lung Cancer
publication date: 2018-05-05T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Risk stratification for elderly patients: Assessing who should be treated
author list: Sequist LV
published in: New approaches to lung cancer: Treating elderly patients
information resource reference: Risk stratification for elderly patients: Assessing who should be treated. New approaches to lung cancer: Treating elderly patients. 2005; 16-19.
publication date: 2005-09-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1074550
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
PubMed Identifier: 29885479
author list: Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 09; 13(9):1248-1268.
journal title abbreviation: J Thorac Oncol
publication date: 2018-06-06T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Review of EGFR Inhibitors in Lung Cancer
author list: Sequist LV, Lynch TJ.
published in: Oncology
information resource reference: Review of EGFR Inhibitors in Lung Cancer. Oncology. 2005; 19(13):1711-1720.
publication date: 2005-11-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Chapter 22. Epidermal Growth Factor Receptor Inhibitors
author list: Sequist LV, Lynch TJ
published in: Lung Cancer (Roth, Cox and Hong).
information resource reference: Chapter 22. Epidermal Growth Factor Receptor Inhibitors. Lung Cancer (Roth, Cox and Hong). 2007.
publication date: 2007-01-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Non-small cell lung cancer
author list: Sequist LV.
published in: Harrison's Manual of Oncolgy. Bruce A. Chabner, Thomas J. Lynch, Jr. and Dan L. Longo (eds.)
information resource reference: Non-small cell lung cancer. Harrison's Manual of Oncolgy. Bruce A. Chabner, Thomas J. Lynch, Jr. and Dan L. Longo (eds.). 2008.
publication date: 2008-01-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.
PubMed Identifier: 20930119
author list: Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010 Oct 26; 107(43):18392-7.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2010-10-07T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
PubMed Identifier: 20979469
author list: Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ
published in: The New England journal of medicine
information resource reference: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
journal title abbreviation: N Engl J Med
publication date: 2010-10-28T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Update on epidermal growth factor receptor inhibitor development in lung cancer.
PubMed Identifier: 17409951
author list: Sequist LV, Dziadziuszko R
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Update on epidermal growth factor receptor inhibitor development in lung cancer. J Thorac Oncol. 2006 Sep; 1(7):740-3.
journal title abbreviation: J Thorac Oncol
publication date: 2006-09-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
PubMed Identifier: 20627894
author list: Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV
published in: Neuro-oncology
information resource reference: EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010 Nov; 12(11):1193-9.
journal title abbreviation: Neuro Oncol
publication date: 2010-07-13T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
PubMed Identifier: 20940188
author list: Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010 Nov 20; 28(33):4953-60.
journal title abbreviation: J Clin Oncol
publication date: 2010-10-12T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
PubMed Identifier: 16818686
author list: Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.
journal title abbreviation: Clin Cancer Res
publication date: 2006-07-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
PubMed Identifier: 22508823
author list: Neal JW, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2012 Jun 20; 30(18):2280-2.
journal title abbreviation: J Clin Oncol
publication date: 2012-04-16T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Detection of impaired homologous recombination repair in NSCLC cells and tissues.
PubMed Identifier: 23399959
author list: Birkelbach M, Ferraiolo N, Gheorghiu L, Pfäffle HN, Daly B, Ebright MI, Spencer C, O'Hara C, Whetstine JR, Benes CH, Sequist LV, Zou L, Dahm-Daphi J, Kachnic LA, Willers H
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol. 2013 Mar; 8(3):279-86.
journal title abbreviation: J Thorac Oncol
publication date: 2013-03-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1085377
type: Authorship
author rank in publication: 12
linked author: Sequist, Lecia
linked information resource: Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
PubMed Identifier: 30060089
author list: Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2018 10 01; 29(10):2143.
journal title abbreviation: Ann Oncol
publication date: 2018-10-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1086876
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
PubMed Identifier: 30077125
author list: Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
journal title abbreviation: Eur J Cancer
publication date: 2018-08-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.
PubMed Identifier: 18520299
author list: Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S143-5.
journal title abbreviation: J Thorac Oncol
publication date: 2008-06-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1088376
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.
PubMed Identifier: 30104333
author list: Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S
published in: Cancer discovery
information resource reference: A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov. 2018 10; 8(10):1286-1299.
journal title abbreviation: Cancer Discov
publication date: 2018-08-13T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1089295
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Authorship 1089271
type: Authorship
author rank in publication: 21
linked author: Sequist, Lecia
linked information resource: Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.
PubMed Identifier: 30123863
author list: Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV
published in: JCO precision oncology
information resource reference: Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precis Oncol. 2018; 2018.
journal title abbreviation: JCO Precis Oncol
publication date: 2018-07-16T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
PubMed Identifier: 30138764
author list: Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):124-129.
journal title abbreviation: J Thorac Oncol
publication date: 2018-08-21T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
PubMed Identifier: 20118973
author list: Neal JW, Sequist LV
published in: Nature reviews. Clinical oncology
information resource reference: Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nat Rev Clin Oncol. 2010 Feb; 7(2):71-2.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2010-02-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
PubMed Identifier: 21632451
author list: Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV
published in: The oncologist
information resource reference: Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011; 16(6):886-95.
journal title abbreviation: Oncologist
publication date: 2011-05-31T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1090550
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
PubMed Identifier: 30154228
author list: Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 12 15; 24(24):6548-6555.
journal title abbreviation: Clin Cancer Res
publication date: 2018-08-28T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
PubMed Identifier: 30205166
author list: Lin JJ, Chin E, Yeap BY, Ferris LA, Kamesan V, Lennes IT, Sequist LV, Heist RS, Mino-Kenudson M, Gainor JF, Shaw AT
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):135-140.
journal title abbreviation: J Thorac Oncol
publication date: 2018-09-08T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
PubMed Identifier: 20129249
author list: Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA
published in: Cancer cell
information resource reference: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19; 17(1):77-88.
journal title abbreviation: Cancer Cell
publication date: 2010-01-19T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1094051
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.

Authorship 1094170
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.

Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.
PubMed Identifier: 30239509
author list: Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV
published in: Clinical journal of oncology nursing
information resource reference: Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. Clin J Oncol Nurs. 2018 10 01; 22(5):542-548.
journal title abbreviation: Clin J Oncol Nurs
publication date: 2018-10-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
PubMed Identifier: 21339258
author list: Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV
published in: The oncologist
information resource reference: Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist. 2011; 16(3):319-26.
journal title abbreviation: Oncologist
publication date: 2011-02-21T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Lung cancer screening.
PubMed Identifier: 22308518
author list: Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, Klippenstein D, Lackner RP, Leard L, Leung AN, Massion PP, Meyers BF, Munden RF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Schabath MB, Sequist LV, Tong BC, Travis WD, Unger M, Yang SC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Lung cancer screening. J Natl Compr Canc Netw. 2012 Feb; 10(2):240-65.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2012-02-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
PubMed Identifier: 30257958
author list: Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV
published in: Cancer discovery
information resource reference: Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
journal title abbreviation: Cancer Discov
publication date: 2018-09-26T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
PubMed Identifier: 22586683
author list: Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC
published in: Cancer discovery
information resource reference: Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25.
journal title abbreviation: Cancer Discov
publication date: 2011-10-17T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 107370
type: Authorship
author rank in publication: 18
linked author: Sequist, Lecia
linked information resource: Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.

Authorship 1095544
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

Authorship 1096533
type: Authorship
author rank in publication: 27
linked author: Sequist, Lecia
linked information resource: Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Authorship 1097447
type: Authorship
author rank in publication: 20
linked author: Sequist, Lecia
linked information resource: Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.
PubMed Identifier: 30254092
author list: Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN
published in: Cancer discovery
information resource reference: Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2018 12; 8(12):1598-1613.
journal title abbreviation: Cancer Discov
publication date: 2018-09-25T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.
PubMed Identifier: 30244855
author list: Piotrowska Z, Fintelmann FJ, Sequist LV, Jahagirdar B
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma. J Thorac Oncol. 2018 10; 13(10):e204-e206.
journal title abbreviation: J Thorac Oncol
publication date: 2018-10-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1108815
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
PubMed Identifier: 30351341
author list: Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 10 01; 29(10):2092-2097.
journal title abbreviation: Ann Oncol
publication date: 2018-10-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.
PubMed Identifier: 20424012
author list: Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S
published in: Science translational medicine
information resource reference: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010 Mar 31; 2(25):25ra23.
journal title abbreviation: Sci Transl Med
publication date: 2010-03-31T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
PubMed Identifier: 20808253
author list: Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010 Oct; 5(10):1637-43.
journal title abbreviation: J Thorac Oncol
publication date: 2010-10-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
PubMed Identifier: 22878749
author list: Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1602-8.
journal title abbreviation: J Thorac Oncol
publication date: 2012-10-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1109568
type: Authorship
author rank in publication: 22
linked author: Sequist, Lecia
linked information resource: Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.
PubMed Identifier: 30370396
author list: Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK
published in: JCO precision oncology
information resource reference: Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
journal title abbreviation: JCO Precis Oncol
publication date: 2018-07-24T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status.
author list: Sequist LV, Jänne P, Walker J, Sweeney J, Grayzel D, Lynch TJ
published in: Proceedings of the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
information resource reference: Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status. . Proceedings of the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2007; abstract 812.
publication date: 2007-10-22T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1114092
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

Authorship 1115406
type: Authorship
author rank in publication: 17
linked author: Sequist, Lecia
linked information resource: SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
PubMed Identifier: 30429032
author list: Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V
published in: Lung cancer (Amsterdam, Netherlands)
information resource reference: Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 11; 125:273-281.
journal title abbreviation: Lung Cancer
publication date: 2018-08-25T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
PubMed Identifier: 30444685
author list: Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2019 01 10; 37(2):97-104.
journal title abbreviation: J Clin Oncol
publication date: 2018-11-16T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
PubMed Identifier: 16131571
author list: Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM
published in: Blood
information resource reference: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96.
journal title abbreviation: Blood
publication date: 2005-08-30T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1117766
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
PubMed Identifier: 30512189
author list: Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G
published in: Cancer
information resource reference: Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 03 15; 125(6):892-901.
journal title abbreviation: Cancer
publication date: 2018-12-04T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
PubMed Identifier: 20386533
author list: Neal JW, Sequist LV
published in: Clinical advances in hematology & oncology : H&O
information resource reference: First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol. 2010 Feb; 8(2):119-26.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2010-02-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1119398
type: Authorship
author rank in publication: 21
linked author: Sequist, Lecia
linked information resource: EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Authorship 1120886
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
PubMed Identifier: 30529597
author list: Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2019 03; 14(3):553-559.
journal title abbreviation: J Thorac Oncol
publication date: 2018-12-04T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
PubMed Identifier: 30550363
author list: Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
journal title abbreviation: J Clin Oncol
publication date: 2018-12-14T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.
PubMed Identifier: 22753908
author list: Moran T, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol. 2012 Sep 20; 30(27):3330-6.
journal title abbreviation: J Clin Oncol
publication date: 2012-07-02T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
PubMed Identifier: 30608433
author list: Digumarthy SR, Padole AM, Gullo RL, Sequist LV, Kalra MK
published in: Medicine
information resource reference: Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? Medicine (Baltimore). 2019 Jan; 98(1):e13963.
journal title abbreviation: Medicine (Baltimore)
publication date: 2019-01-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1123528
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
PubMed Identifier: 16857818
author list: Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s.
journal title abbreviation: Clin Cancer Res
publication date: 2006-07-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
PubMed Identifier: 18458038
author list: Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20; 26(15):2442-9.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-05T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular analysis-based treatment strategies for the management of non-small cell lung cancer.
PubMed Identifier: 19704347
author list: West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9 Suppl 2):S1029-39; quiz S1041-2.
journal title abbreviation: J Thorac Oncol
publication date: 2009-09-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 119361
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.

Protein Kinase Inhibitors
MeSH DescriptorUI: D047428
MeSH semantic group name: Chemicals & Drugs
number of authors: 1636
number of publications: 6078
uniqueness weight: 0.299751
type: Concept

Carcinoma, Non-Small-Cell Lung
MeSH DescriptorUI: D002289
MeSH semantic group name: Disorders
number of authors: 1102
number of publications: 5718
uniqueness weight: 0.259527
type: Concept

Authorship 1142403
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Authorship 1146568
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
PubMed Identifier: 30885353
author list: Gubens MA, Sequist LV, Stevenson JP, Powell SF, Villaruz LC, Gadgeel SM, Langer CJ, Patnaik A, Borghaei H, Jalal SI, Fiore J, Saraf S, Raftopoulos H, Gandhi L
published in: Lung cancer (Amsterdam, Netherlands)
information resource reference: Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 2019 04; 130:59-66.
journal title abbreviation: Lung Cancer
publication date: 2018-12-17T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
PubMed Identifier: 30975923
author list: Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA
published in: The oncologist
information resource reference: Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist. 2019 08; 24(8):1095-1102.
journal title abbreviation: Oncologist
publication date: 2019-04-11T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Lung Neoplasms
MeSH DescriptorUI: D008175
MeSH semantic group name: Disorders
number of authors: 2605
number of publications: 14119
uniqueness weight: 0.173058
type: Concept

Acrylamides
MeSH DescriptorUI: D000178
MeSH semantic group name: Chemicals & Drugs
number of authors: 159
number of publications: 309
uniqueness weight: 0.838759
type: Concept

Authorship 1149869
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.

Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.
PubMed Identifier: 31032471
author list: Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV
published in: JCO precision oncology
information resource reference: Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 1.
journal title abbreviation: JCO Precis Oncol
publication date: 2017-11-07T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Quinazolines
MeSH DescriptorUI: D011799
MeSH semantic group name: Chemicals & Drugs
number of authors: 467
number of publications: 1368
uniqueness weight: 0.622703
type: Concept

Emeritus
type: Department
type: Organization

Environmental Health
type: Department
type: Organization

Medicine
type: Department
type: Organization

Radiology
type: Department
type: Organization

Surgery
type: Department
type: Organization

Hematology/Oncology
type: Division
type: Organization

Cardiology
type: Division
type: Organization

Endocrinology
type: Division
type: Organization

Oncology
type: Division
type: Organization

Beth Israel Deaconess Medical Center
type: Organization

Dana-Farber Cancer Institute
type: Organization

Harvard Medical School
type: Organization

Harvard T.H. Chan School of Public Health
type: Organization

Massachusetts General Hospital
type: Organization

Christiani, David
eCommons Login: DCC5
first name: David
last name: Christiani
full name: David Christopher Christiani, M.D.
has faculty rank: Full Professor
latitude: 42.33570000000000
longitude: -71.10169990000000
photo: https://connects.catalyst.harvard.edu/Profiles/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx
Person ID: 14998
person in primary position: Elkan Blout Professor of Environmental Genetics
type: Agent
type: Person
preferred title: Elkan Blout Professor of Environmental Genetics

Authorship 1152357
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.

Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
PubMed Identifier: 31099642
author list: Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ
published in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
information resource reference: Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e187-e197.
journal title abbreviation: Am Soc Clin Oncol Educ Book
publication date: 2019-05-17T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.
PubMed Identifier: 31113818
author list: Grassberger C, McClatchy D, Geng C, Kamran SC, Fintelmann F, Maruvka YE, Piotrowska Z, Willers H, Sequist LV, Hata AN, Paganetti H
published in: Cancer research
information resource reference: Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Res. 2019 07 15; 79(14):3776-3788.
journal title abbreviation: Cancer Res
publication date: 2019-05-21T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1156578
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Authorship 1156938
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer.

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer.
PubMed Identifier: 31152082
author list: Fintelmann FJ, Troschel FM, Kuklinski MW, McDermott S, Petranovic M, Digumarthy SR, Sharma A, Troschel AS, Price MC, Hariri LP, Gilman MD, Shepard JO, Sequist LV, Piotrowska Z
published in: The oncologist
information resource reference: Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. Oncologist. 2019 12; 24(12):1570-1576.
journal title abbreviation: Oncologist
publication date: 2019-05-31T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Kopans, Daniel
eCommons Login: DBK1
first name: Daniel
last name: Kopans
full name: Daniel Benjamin Kopans, M.D.
has faculty rank: Full Professor
latitude: 42.36239000000000
longitude: -71.06931690000000
Person ID: 11351
person in primary position: Professor of Radiology, Emeritus
type: Agent
type: Person
preferred title: Professor of Radiology, Emeritus

Heist, Rebecca
eCommons Login: CRS3
first name: Rebecca
last name: Heist
full name: Rebecca Suk Heist, M.D.
has faculty rank: Full Professor
latitude: 42.36241700000000
longitude: -71.06893700000000
Person ID: 79396
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

selected publications
maximum weight: 1
minimum weight: 1
number of connections: 332
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/113
predicate: selected publications
type: Network

research areas
maximum weight: 9.17952
minimum weight: 0.00475103
number of connections: 539
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/217
predicate: research areas
type: Network

coauthor of
maximum weight: 8.68809
minimum weight: 0.0148136
number of connections: 213
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/363
predicate: coauthor of
type: Network

similar to
maximum weight: 322.253
minimum weight: 57.9894
number of connections: 60
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/494
predicate: similar to
type: Network

Piotrowska, Zofia
eCommons Login: ZP6
first name: Zofia
last name: Piotrowska
full name: Zofia Piotrowska, M.D.
has faculty rank: Associate Professor
latitude: 42.33510370000000
longitude: -71.10616490000000
Person ID: 60422
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Barbesino, Giuseppe
eCommons Login: GB31
first name: Giuseppe
last name: Barbesino
full name: Giuseppe Barbesino, M.D.
has faculty rank: Assistant Professor
latitude: 42.36239000000000
longitude: -71.06931690000000
Person ID: 18248
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

Johnson, Bruce
eCommons Login: BEJ1
first name: Bruce
last name: Johnson
full name: Bruce Evan Johnson, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 46357
person in primary position: Professor of Medicine, Emeritus
type: Agent
type: Person
preferred title: Professor of Medicine, Emeritus

Saini, Sanjay
eCommons Login: SS35
first name: Sanjay
last name: Saini
full name: Sanjay Saini, M.D.
has faculty rank: Full Professor
latitude: 42.36239000000000
longitude: -71.06931690000000
Person ID: 12917
person in primary position: Professor of Radiology
type: Agent
type: Person
preferred title: Professor of Radiology

Authorship 125305
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!

Randolph, Mark
eCommons Login: MAR2
first name: Mark
last name: Randolph
full name: Mark A. Randolph, M.A.Sc.
has faculty rank: Assistant Professor
latitude: 42.36239000000000
longitude: -71.06931690000000
Person ID: 28292
person in primary position: Assistant Professor of Surgery
type: Agent
type: Person
preferred title: Assistant Professor of Surgery

Passeri, Jonathan
eCommons Login: JJP3
first name: Jonathan
last name: Passeri
full name: Jonathan James Passeri, M.D.
has faculty rank: Assistant Professor
latitude: 42.36239000000000
longitude: -71.06931690000000
Person ID: 67860
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

Authorship 1160923
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

Authorship 1161258
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.

Authorship 1162190
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?

Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?
PubMed Identifier: 31182167
author list: Digumarthy SR, Padole AM, Rastogi S, Price M, Mooradian MJ, Sequist LV, Kalra MK
published in: Cancer imaging : the official publication of the International Cancer Imaging Society
information resource reference: Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT? Cancer Imaging. 2019 Jun 10; 19(1):36.
journal title abbreviation: Cancer Imaging
publication date: 2019-06-10T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.
PubMed Identifier: 31216465
author list: Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H
published in: Cell reports
information resource reference: Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Rep. 2019 06 18; 27(12):3422-3432.e4.
journal title abbreviation: Cell Rep
publication date: 2019-06-18T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
PubMed Identifier: 31200814
author list: Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC
published in: Lung cancer (Amsterdam, Netherlands)
information resource reference: First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 2019 07; 133:10-19.
journal title abbreviation: Lung Cancer
publication date: 2019-04-08T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 134664
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Gainor, Justin
eCommons Login: JFG5
first name: Justin
last name: Gainor
full name: Justin Franklin Gainor, M.D.
has faculty rank: Associate Professor
latitude: 42.36241700000000
longitude: -71.06893700000000
Person ID: 64512
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Shaw, Alice
eCommons Login: APT1
first name: Alice
last name: Shaw
full name: Alice Tsang Shaw, M.D., Ph.D.
has faculty rank: Full Professor
latitude: 42.36241700000000
longitude: -71.06893700000000
Person ID: 7296
person in primary position: George P. Canellos, MD, and Jean S. Canellos Professor of Medicine Professor of Medicine
type: Agent
type: Person
preferred title: George P. Canellos, MD, and Jean S. Canellos Professor of Medicine Professor of Medicine

Costa, Daniel
eCommons Login: DBC4
first name: Daniel
last name: Costa
full name: Daniel Botelho Costa, M.D., Ph.D.
has faculty rank: Full Professor
latitude: 42.34022770000000
longitude: -71.10585400000000
photo: https://connects.catalyst.harvard.edu/Profiles/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx
Person ID: 17541
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Dagogo-Jack, Ibiayi
eCommons Login: ID30
first name: Ibiayi
last name: Dagogo-Jack
full name: Ibiayi Dagogo-Jack, M.D.
has faculty rank: Associate Professor
Person ID: 100079
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Authorship 1175338
type: Authorship
author rank in publication: 22
linked author: Sequist, Lecia
linked information resource: Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
PubMed Identifier: 31324888
author list: Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, Greenberg M, Williams A, Kattermann K, Damon L, Sovath S, Rakiec DP, Korn JM, Ruddy DA, Benes CH, Hammerman PS, Piotrowska Z, Sequist LV, Niederst MJ, Barretina J, Engelman JA, Hata AN
published in: Oncogene
information resource reference: Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019 09; 38(37):6399-6413.
journal title abbreviation: Oncogene
publication date: 2019-07-19T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 126027
type: Authorship
author rank in publication: 15
linked author: Sequist, Lecia
linked information resource: Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
PubMed Identifier: 31416802
author list: Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, Digumarthy SR, Sequist LV, Hata AN, Maheswaran S, Haber DA, Lawrence MS, Shaw AT, Mino-Kenudson M, Dyson NJ, Drapkin BJ
published in: Cancer discovery
information resource reference: Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019 10; 9(10):1372-1387.
journal title abbreviation: Cancer Discov
publication date: 2019-08-15T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1182669
type: Authorship
author rank in publication: 17
linked author: Sequist, Lecia
linked information resource: Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.

Authorship 1187065
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear.

Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear.
PubMed Identifier: 31492767
author list: Peppercorn J, Campbell E, Isakoff S, Horick NK, Rabin J, Quain K, Sequist LV, Bardia A, Collyar D, Hlubocky F, Mathews D
published in: The oncologist
information resource reference: Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. Oncologist. 2020 01; 25(1):78-86.
journal title abbreviation: Oncologist
publication date: 2019-09-06T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 144870
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.

Authorship 1191761
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.
PubMed Identifier: 31540242
author list: Digumarthy SR, Mendoza DP, Padole A, Chen T, Peterson PG, Piotrowska Z, Sequist LV
published in: Cancers
information resource reference: Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. Cancers (Basel). 2019 Sep 13; 11(9).
journal title abbreviation: Cancers (Basel)
publication date: 2019-09-13T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1192101
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.
PubMed Identifier: 31558234
author list: Dagogo-Jack I, Piotrowska Z, Cobb R, Banwait M, Lennerz JK, Hata AN, Digumarthy SR, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. J Thorac Oncol. 2019 10; 14(10):e226-e228.
journal title abbreviation: J Thorac Oncol
publication date: 2019-10-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
PubMed Identifier: 31708389
author list: Digumarthy SR, Mendoza DP, Lin JJ, Chen T, Rooney MM, Chin E, Sequist LV, Lennerz JK, Gainor JF, Shaw AT
published in: Clinical lung cancer
information resource reference: Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. Clin Lung Cancer. 2020 03; 21(2):153-159.e3.
journal title abbreviation: Clin Lung Cancer
publication date: 2019-10-16T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 135029
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1046641

Authorship 1204769
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.

Authorship 1205348
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.

A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.
PubMed Identifier: 31732522
author list: Dizier B, Callegaro A, Debois M, Dreno B, Hersey P, Gogas HJ, Kirkwood JM, Vansteenkiste JF, Sequist LV, Atanackovic D, Goeman J, van Houwelingen H, Salceda S, Wang F, Therasse P, Debruyne C, Spiessens B, Brichard VG, Louahed J, Ulloa-Montoya F
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 04 01; 26(7):1725-1735.
journal title abbreviation: Clin Cancer Res
publication date: 2019-11-15T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Landry Family Professor of Medicine in the Field of Medical Oncology
is primary position: true
position in department: Medicine
position in division: Hematology/Oncology
sort order: 1
type: Position
HR job title: Landry Family Professor of Medicine in the Field of Medical Oncology
position in organization: Massachusetts General Hospital

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Cardiology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Massachusetts General Hospital

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Endocrinology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Massachusetts General Hospital

Assistant Professor of Surgery
is primary position: true
position in department: Surgery
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Assistant Professor of Surgery
position in organization: Massachusetts General Hospital

Authorship 133140
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Authorship 135848
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Authorship 1214124
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations.

Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations.
PubMed Identifier: 31876321
author list: Roberts TJ, Lennes IT, Hawari S, Sequist LV, Park ER, Willers H, Frank A, Gaissert H, Shepard JA, Ryan D
published in: The oncologist
information resource reference: Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist. 2020 05; 25(5):431-437.
journal title abbreviation: Oncologist
publication date: 2019-12-26T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.
PubMed Identifier: 31887093
author list: Mendoza DP, Lin JJ, Rooney MM, Chen T, Sequist LV, Shaw AT, Digumarthy SR
published in: AJR. American journal of roentgenology
information resource reference: Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer. AJR Am J Roentgenol. 2020 04; 214(4):766-774.
journal title abbreviation: AJR Am J Roentgenol
publication date: 2019-12-30T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1214663
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.

Authorship 1219685
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
PubMed Identifier: 31988000
author list: Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 04; 15(4):541-549.
journal title abbreviation: J Thorac Oncol
publication date: 2020-01-24T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
PubMed Identifier: 31954624
author list: Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW
published in: The Lancet. Respiratory medicine
information resource reference: Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020 06; 8(6):561-572.
journal title abbreviation: Lancet Respir Med
publication date: 2020-01-15T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1221432
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

Authorship 1223773
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/144978836

https://connects.catalyst.harvard.edu/Profiles/profile/144978836
PubMed Identifier: 32027846
author list: Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G
published in: The Lancet. Oncology
information resource reference: Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 03; 21(3):373-386.
journal title abbreviation: Lancet Oncol
publication date: 2020-02-03T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

Authorship 129620
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Isolation of rare circulating tumour cells in cancer patients by microchip technology.

Authorship 1239138
type: Authorship
author rank in publication: 46
linked author: Sequist, Lecia
linked information resource: Integrating genomic features for non-invasive early lung cancer detection.

Integrating genomic features for non-invasive early lung cancer detection.
PubMed Identifier: 32269342
author list: Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, Jeon YJ, Nesselbush MC, Co Ting Keh L, Bonilla RF, Yoo CH, Ko RB, Chen EL, Merriott DJ, Massion PP, Mansfield AS, Jen J, Ren HZ, Lin SH, Costantino CL, Burr R, Tibshirani R, Gambhir SS, Berry GJ, Jensen KC, West RB, Neal JW, Wakelee HA, Loo BW, Kunder CA, Leung AN, Lui NS, Berry MF, Shrager JB, Nair VS, Haber DA, Sequist LV, Alizadeh AA, Diehn M
published in: Nature
information resource reference: Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020 04; 580(7802):245-251.
journal title abbreviation: Nature
publication date: 2020-03-25T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 175284
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.

Authorship 1243515
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
PubMed Identifier: 32358026
author list: Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277.
journal title abbreviation: Clin Cancer Res
publication date: 2020-05-01T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1256455
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review.

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review.
PubMed Identifier: 32552277
author list: Piper-Vallillo AJ, Sequist LV, Piotrowska Z
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. J Clin Oncol. 2020 Jun 18; JCO1903123.
journal title abbreviation: J Clin Oncol
publication date: 2020-06-18T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1259869
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.

Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
PubMed Identifier: 32586767
author list: Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O'Hear C, Fassò M, Lam S, Gordon MS
published in: Clinical lung cancer
information resource reference: Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4.
journal title abbreviation: Clin Lung Cancer
publication date: 2020-05-12T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 146328
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Non-small cell lung cancer in octogenarians: treatment practices and preferences.

Authorship 157565
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

Authorship 1269396
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.
PubMed Identifier: 32700141
author list: Santos ES, Kaplan B, Kirshner E, Croft EF, Sequist LV, Chau M, Munley J, Oxnard GR
published in: Oncology and therapy
information resource reference: Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. Oncol Ther. 2018 Jun; 6(1):45-58.
journal title abbreviation: Oncol Ther
publication date: 2018-05-25T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1272429
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis.

Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis.
PubMed Identifier: 32755209
author list: Mendoza DP, Heeger A, Mino-Kenudson M, Lanuti M, Shepard JO, Sequist LV, Digumarthy SR
published in: AJR. American journal of roentgenology
information resource reference: Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2021 02; 216(2):318-329.
journal title abbreviation: AJR Am J Roentgenol
publication date: 2020-12-23T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1287805
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.

Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.
PubMed Identifier: 32907839
author list: McClatchy DM, Willers H, Hata AN, Piotrowska Z, Sequist LV, Paganetti H, Grassberger C
published in: Cancer research
information resource reference: Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Res. 2020 11 15; 80(22):5121-5133.
journal title abbreviation: Cancer Res
publication date: 2020-09-09T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 206803
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.

Authorship 1291548
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
PubMed Identifier: 33007380
author list: Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S, Peterson J, Do A, Prutisto-Chang K, Dagogo-Jack I, Sequist LV, Wirth LJ, Lennerz JK, Hata AN, Mino-Kenudson M, Nardi V, Ou SI, Tan DS, Gainor JF
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020 12; 31(12):1725-1733.
journal title abbreviation: Ann Oncol
publication date: 2020-09-29T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1297738
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
PubMed Identifier: 33069888
author list: Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 01; 16(1):162-168.
journal title abbreviation: J Thorac Oncol
publication date: 2020-10-15T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1303548
type: Authorship
author rank in publication: 20
linked author: Sequist, Lecia
linked information resource: Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations.

Authorship 1306785
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients.

Authorship 1303488
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.

Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients.
PubMed Identifier: 33189594
author list: Garrana SH, Dagogo-Jack I, Cobb R, Kuo AH, Mendoza DP, Zhang EW, Heeger A, Sequist LV, Digumarthy SR
published in: Clinical lung cancer
information resource reference: Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients. Clin Lung Cancer. 2021 01; 22(1):23-31.
journal title abbreviation: Clin Lung Cancer
publication date: 2020-10-21T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.
PubMed Identifier: 33188913
author list: Sands J, Tammemägi MC, Couraud S, Baldwin DR, Borondy-Kitts A, Yankelevitz D, Lewis J, Grannis F, Kauczor HU, von Stackelberg O, Sequist L, Pastorino U, McKee B
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation. J Thorac Oncol. 2021 01; 16(1):37-53.
journal title abbreviation: J Thorac Oncol
publication date: 2020-11-12T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations.
PubMed Identifier: 33205053
author list: Piper-Vallillo AJ, Mooradian MJ, Meador CB, Yeap BY, Peterson J, Sakhi M, Do A, Zubiri L, Stevens S, Vaughn J, Goodwin K, Gavralidis A, Willers H, Miller A, Farago A, Piotrowska Z, Lin JJ, Dagogo-Jack I, Lennes IT, Sequist LV, Temel JS, Heist RS, Digumarthy S, Reynolds KL, Gainor JF
published in: JTO clinical and research reports
information resource reference: Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124.
journal title abbreviation: JTO Clin Res Rep
publication date: 2020-11-12T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1323812
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: A New Era of Protein-Based Assays for Cancer Early Detection.

A New Era of Protein-Based Assays for Cancer Early Detection.
PubMed Identifier: 33494925
author list: Sequist LV, Skates SJ, Haas W
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: A New Era of Protein-Based Assays for Cancer Early Detection. J Thorac Oncol. 2021 02; 16(2):191-193.
journal title abbreviation: J Thorac Oncol
publication date: 2021-02-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Co-Principal Investigator
type: Researcher Role
researcher role of: Sequist, Lecia
contributes to: Training Program in Cancer Biology and Therapeutics

Authorship 1324980
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
PubMed Identifier: 33545388
author list: Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN, Heist RS
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 05; 16(5):850-859.
journal title abbreviation: J Thorac Oncol
publication date: 2021-02-03T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1333211
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
PubMed Identifier: 33610453
author list: White MN, Piotrowska Z, Stirling K, Liu SV, Banwait MK, Cunanan K, Sequist LV, Wakelee HA, Hausrath D, Neal JW
published in: Clinical lung cancer
information resource reference: Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clin Lung Cancer. 2021 05; 22(3):201-209.
journal title abbreviation: Clin Lung Cancer
publication date: 2021-01-27T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
PubMed Identifier: 33685866
author list: Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 05 15; 27(10):2899-2909.
journal title abbreviation: Clin Cancer Res
publication date: 2021-03-08T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1338158
type: Authorship
author rank in publication: 19
linked author: Sequist, Lecia
linked information resource: Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Hematology/Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Massachusetts General Hospital

Authorship 164868
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

Authorship 1370031
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.
PubMed Identifier: 34151132
author list: Neal JW, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramachandran KJ, Rangachari D, Huberman MS, Piotrowska Z, Kris MG, Azzoli CG, Sequist LV, Chaft JE
published in: JCO precision oncology
information resource reference: Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021 01; 5:325-332.
journal title abbreviation: JCO Precis Oncol
publication date: 2021-02-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1374249
type: Authorship
author rank in publication: 16
linked author: Sequist, Lecia
linked information resource: Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
PubMed Identifier: 34246791
author list: Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 10; 16(10):1647-1662.
journal title abbreviation: J Thorac Oncol
publication date: 2021-07-08T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1377089
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Lung cancer.

Authorship 1378236
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.

Lung cancer.
PubMed Identifier: 34273294
author list: Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS
published in: Lancet (London, England)
information resource reference: Lung cancer. Lancet. 2021 08 07; 398(10299):535-554.
journal title abbreviation: Lancet
publication date: 2021-07-21T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.
PubMed Identifier: 34301786
author list: Meador CB, Sequist LV, Piotrowska Z
published in: Cancer discovery
information resource reference: Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discov. 2021 09; 11(9):2145-2157.
journal title abbreviation: Cancer Discov
publication date: 2021-07-23T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1386534
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib.

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib.
PubMed Identifier: 34396180
author list: Piper-Vallillo AJ, Sequist LV
published in: JACC. CardioOncology
information resource reference: Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib. JACC CardioOncol. 2019 Dec; 1(2):179-181.
journal title abbreviation: JACC CardioOncol
publication date: 2019-12-17T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1399367
type: Authorship
author rank in publication: 25
linked author: Sequist, Lecia
linked information resource: Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

Authorship 1399233
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde.

Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde.
PubMed Identifier: 34589988
author list: Wysota M, Asiry S, Goldstein Y, Sequist LV, Khader S, Halmos B
published in: JTO clinical and research reports
information resource reference: Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde. JTO Clin Res Rep. 2021 Feb; 2(2):100128.
journal title abbreviation: JTO Clin Res Rep
publication date: 2020-12-03T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.
PubMed Identifier: 34624218
author list: Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, Noeen S, Kattermann K, Greenberg M, Williams A, Riley AK, Wilson JJ, Mao YQ, Huang RP, Banwait MK, Ho J, Crowther GS, Hariri LP, Heist RS, Kodack DP, Pinello L, Shaw AT, Mino-Kenudson M, Hata AN, Sequist LV, Benes CH, Niederst MJ, Engelman JA
published in: Cancer cell
information resource reference: Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021 11 08; 39(11):1531-1547.e10.
journal title abbreviation: Cancer Cell
publication date: 2021-10-07T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.
PubMed Identifier: 34896762
author list: Lin JJ, Muzikansky A, Kennedy E, Kuberski H, Stober LL, Wanat AC, Azzoli CG, Lennes I, Sequist LV, Dagogo-Jack I, Shaw AT, Gainor JF
published in: ESMO open
information resource reference: Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open. 2022 02; 7(1):100342.
journal title abbreviation: ESMO Open
publication date: 2021-12-09T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1417383
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
PubMed Identifier: 34887193
author list: White MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA
published in: Clinical lung cancer
information resource reference: Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clin Lung Cancer. 2022 05; 23(3):e210-e221.
journal title abbreviation: Clin Lung Cancer
publication date: 2021-11-11T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1419222
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.

LTK fusions: A new target emerges in non-small cell lung cancer.
PubMed Identifier: 35016028
author list: Cooper AJ, Sequist LV, Johnson TW, Lin JJ
published in: Cancer cell
information resource reference: LTK fusions: A new target emerges in non-small cell lung cancer. Cancer Cell. 2022 01 10; 40(1):23-25.
journal title abbreviation: Cancer Cell
publication date: 2022-01-10T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 165928
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.

Authorship 1425993
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: LTK fusions: A new target emerges in non-small cell lung cancer.

Authorship 1431964
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

Authorship 1432321
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: A bright future for KRAS inhibitors.

A bright future for KRAS inhibitors.
PubMed Identifier: 35121842
author list: Bar-Sagi D, Knelson EH, Sequist LV
published in: Nature cancer
information resource reference: A bright future for KRAS inhibitors. Nat Cancer. 2020 01; 1(1):25-27.
journal title abbreviation: Nat Cancer
publication date: 2020-01-01T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
PubMed Identifier: 35135111
author list: Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, Reckamp KL, Camidge DR, Pérol M, Ou SI, Liu SV, Yu HA, Soria JC, Socinski MA, Mekhail TM, Solomon BJ, Natale RB, Otterson GA, Papadimitrakopoulou V, Langer CJ, Neal JW, Despain D, Yurasov S, Litten JB, Erlander M, Raponi M, Wakelee HA
published in: JCO precision oncology
information resource reference: EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2018 Nov; 2:1-13.
journal title abbreviation: JCO Precis Oncol
publication date: 2018-11-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1442057
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic.

Authorship 1440999
type: Authorship
author rank in publication: 25
linked author: Sequist, Lecia
linked information resource: ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
PubMed Identifier: 35176458
author list: Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022 05; 33(5):466-487.
journal title abbreviation: Ann Oncol
publication date: 2022-02-14T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic.
PubMed Identifier: 35357454
author list: Milligan MG, Lennes IT, Hawari S, Khandekar MJ, Colson Y, Shepard JO, Frank A, Sequist LV, Willers H, Keane FK
published in: JAMA network open
information resource reference: Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic. JAMA Netw Open. 2022 03 01; 5(3):e224840.
journal title abbreviation: JAMA Netw Open
publication date: 2022-03-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
PubMed Identifier: 35534623
author list: Cooper AJ, Sequist LV, Lin JJ
published in: Nature reviews. Clinical oncology
information resource reference: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022 08; 19(8):499-514.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2022-05-09T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1449468
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Phase II Study of Cabozantinib in Patients With Bone Metastasis.

Phase II Study of Cabozantinib in Patients With Bone Metastasis.
PubMed Identifier: 35524758
author list: Choy E, Cote GM, Michaelson MD, Wirth L, Gainor JF, Muzikansky A, Sequist LV, Sullivan RJ, Fidias PM, Shaw A, Heist RS
published in: The oncologist
information resource reference: Phase II Study of Cabozantinib in Patients With Bone Metastasis. Oncologist. 2022 07 05; 27(7):600-606.
journal title abbreviation: Oncologist
publication date: 2022-07-05T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1450679
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authorship 388646
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer.

Authorship 1466059
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.

Authorship 1465054
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
PubMed Identifier: 35810553
author list: Tan DSW, Kim SW, Ponce Aix S, Sequist LV, Smit EF, Yang JCH, Hida T, Toyozawa R, Felip E, Wolf J, Grohé C, Leighl NB, Riely G, Cui X, Zou M, Ghebremariam S, O'Sullivan-Djentuh L, Belli R, Giovannini M, Kim DW
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur J Cancer. 2022 09; 172:276-286.
journal title abbreviation: Eur J Cancer
publication date: 2022-07-07T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
PubMed Identifier: 35637759
author list: Piper-Vallillo AJ, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml JM, Neal JW, Piotrowska Z
published in: JTO clinical and research reports
information resource reference: High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328.
journal title abbreviation: JTO Clin Res Rep
publication date: 2022-04-21T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
PubMed Identifier: 35971001
author list: Cooper AJ, Sequist LV, Lin JJ
published in: Nature reviews. Clinical oncology
information resource reference: Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022 Nov; 19(11):744.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2022-11-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC.
PubMed Identifier: 36118132
author list: Cooper AJ, Muzikansky A, Lennerz J, Narinesingh F, Mino-Kenudson M, Hung YP, Piotrowska Z, Dagogo-Jack I, Sequist LV, Gainor JF, Lin JJ, Heist RS
published in: JTO clinical and research reports
information resource reference: Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100390.
journal title abbreviation: JTO Clin Res Rep
publication date: 2022-08-08T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1491481
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.

Authorship 1493092
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authorship 1499479
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC.

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
PubMed Identifier: 36264123
author list: Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, Su WC, Kowalski DM, Orlov S, Ren S, Frewer P, Ou X, Cross DAE, Kurian N, Cantarini M, Jänne PA
published in: Cancer discovery
information resource reference: Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023 01 09; 13(1):98-113.
journal title abbreviation: Cancer Discov
publication date: 2023-01-09T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1513874
type: Authorship
author rank in publication: 18
linked author: Sequist, Lecia
linked information resource: Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.

Authorship 1513872
type: Authorship
author rank in publication: 18
linked author: Sequist, Lecia
linked information resource: Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.
PubMed Identifier: 36534935
author list: Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Leighl NB, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2. J Clin Oncol. 2023 02 10; 41(5):e1-e9.
journal title abbreviation: J Clin Oncol
publication date: 2022-12-19T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
PubMed Identifier: 36534938
author list: Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Leighl NB, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2. J Clin Oncol. 2023 02 10; 41(5):e10-e20.
journal title abbreviation: J Clin Oncol
publication date: 2022-12-19T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1516955
type: Authorship
author rank in publication: 15
linked author: Sequist, Lecia
linked information resource: Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.
PubMed Identifier: 36634294
author list: Mikhael PG, Wohlwend J, Yala A, Karstens L, Xiang J, Takigami AK, Bourgouin PP, Chan P, Mrah S, Amayri W, Juan YH, Yang CT, Wan YL, Lin G, Sequist LV, Fintelmann FJ, Barzilay R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography. J Clin Oncol. 2023 04 20; 41(12):2191-2200.
journal title abbreviation: J Clin Oncol
publication date: 2023-01-12T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 201786
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.

Authorship 1573569
type: Authorship
author rank in publication: 33
linked author: Sequist, Lecia
linked information resource: Therapy-induced APOBEC3A drives evolution of persistent cancer cells.

Authorship 1552402
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Expanding the Reach and Grasp of Lung Cancer Screening.

Authorship 1566934
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.

Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
PubMed Identifier: 37407818
author list: Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJ, Maruvka YE, Buisson R, Lawrence MS, Hata AN
published in: Nature
information resource reference: Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature. 2023 08; 620(7973):393-401.
journal title abbreviation: Nature
publication date: 2023-07-05T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Expanding the Reach and Grasp of Lung Cancer Screening.
PubMed Identifier: 37098234
author list: Osarogiagbon RU, Yang PC, Sequist LV
published in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
information resource reference: Expanding the Reach and Grasp of Lung Cancer Screening. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e389958.
journal title abbreviation: Am Soc Clin Oncol Educ Book
publication date: 2023-01-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
PubMed Identifier: 37235976
author list: Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol. 2023 06 01; 41(16):2869-2876.
journal title abbreviation: J Clin Oncol
publication date: 2023-06-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1592557
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis.

Authorship 1583259
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma.

B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma.
PubMed Identifier: 37521368
author list: Dagogo-Jack I, Valiev I, Kotlov N, Belozerova A, Lopareva A, Butusova A, Samarina N, Boyko A, Xiang Z, Johnson M, Degryse S, Keane FK, Sequist LV, Lanuti M, Fowler N, Mino-Kenudson M, Bagaev A
published in: JTO clinical and research reports
information resource reference: B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma. JTO Clin Res Rep. 2023 Jul; 4(7):100527.
journal title abbreviation: JTO Clin Res Rep
publication date: 2023-05-18T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis.
PubMed Identifier: 37533439
author list: Dagogo-Jack I, Kiedrowski LA, Heist RS, Lin JJ, Meador CB, Krueger EA, Do A, Peterson J, Sequist LV, Gainor JF, Lennerz JK, Digumarthy SR
published in: JTO clinical and research reports
information resource reference: Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis. JTO Clin Res Rep. 2023 Aug; 4(8):100534.
journal title abbreviation: JTO Clin Res Rep
publication date: 2023-06-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1596541
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Artificial Intelligence and Machine Learning in Lung Cancer Screening.

Authorship 1596674
type: Authorship
author rank in publication: 20
linked author: Sequist, Lecia
linked information resource: Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer.

Artificial Intelligence and Machine Learning in Lung Cancer Screening.
PubMed Identifier: 37806742
author list: Adams SJ, Mikhael P, Wohlwend J, Barzilay R, Sequist LV, Fintelmann FJ
published in: Thoracic surgery clinics
information resource reference: Artificial Intelligence and Machine Learning in Lung Cancer Screening. Thorac Surg Clin. 2023 Nov; 33(4):401-409.
journal title abbreviation: Thorac Surg Clin
publication date: 2023-05-12T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer.
PubMed Identifier: 37808694
author list: Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, Sequist LV, Lennerz JK, Mino-Kenudson M, Maheswaran S, Naxerova K, Getz G, Haber DA
published in: medRxiv : the preprint server for health sciences
information resource reference: Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer. medRxiv. 2023 Sep 29.
journal title abbreviation: medRxiv
publication date: 2023-09-29T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1598788
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography.

Authorship 1600546
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.

Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography.
PubMed Identifier: 37903855
author list: Simon J, Mikhael P, Tahir I, Graur A, Ringer S, Fata A, Jeffrey YC, Shepard JA, Jacobson F, Barzilay R, Sequist LV, Pace LE, Fintelmann FJ
published in: Scientific reports
information resource reference: Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography. Sci Rep. 2023 10 30; 13(1):18611.
journal title abbreviation: Sci Rep
publication date: 2023-10-30T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.
PubMed Identifier: 37883100
author list: Sequist LV, Warner ET, Yang CJ
published in: JAMA oncology
information resource reference: Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs. JAMA Oncol. 2023 12 01; 9(12):1649-1650.
journal title abbreviation: JAMA Oncol
publication date: 2023-12-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1605103
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint.

Authorship 1605461
type: Authorship
author rank in publication: 12
linked author: Sequist, Lecia
linked information resource: Lung Cancer in Women: The Past, Present, and Future.

Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint.
PubMed Identifier: 37934096
author list: Sequist LV, Olazagasti C
published in: Radiology
information resource reference: Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint. Radiology. 2023 11; 309(2):e232850.
journal title abbreviation: Radiology
publication date: 2023-11-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Lung Cancer in Women: The Past, Present, and Future.
PubMed Identifier: 37940410
author list: Florez N, Kiel L, Riano I, Patel S, DeCarli K, Dhawan N, Franco I, Odai-Afotey A, Meza K, Swami N, Patel J, Sequist LV
published in: Clinical lung cancer
information resource reference: Lung Cancer in Women: The Past, Present, and Future. Clin Lung Cancer. 2024 01; 25(1):1-8.
journal title abbreviation: Clin Lung Cancer
publication date: 2023-10-20T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
end date: 2027-07-31
principal investigator name: BARBIE, DAVID A
start date: 2022-08-01
type: Grant
sponsor award id: P50CA265826

Authorship 1623858
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Deploying blood-based cancer screening.

Deploying blood-based cancer screening.
PubMed Identifier: 38271495
author list: Micalizzi DS, Sequist LV, Haber DA
published in: Science (New York, N.Y.)
information resource reference: Deploying blood-based cancer screening. Science. 2024 01 26; 383(6681):368-370.
journal title abbreviation: Science
publication date: 2024-01-25T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1629945
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.

Authorship 1629947
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
PubMed Identifier: 38417098
author list: Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Apr 10; 42(11):e23-e43.
journal title abbreviation: J Clin Oncol
publication date: 2024-02-28T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
PubMed Identifier: 38417091
author list: Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Apr 10; 42(11):e1-e22.
journal title abbreviation: J Clin Oncol
publication date: 2024-02-28T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1636907
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.

Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
PubMed Identifier: 38537159
author list: Potter AL, Xu NN, Senthil P, Srinivasan D, Lee H, Gazelle GS, Chelala L, Zheng W, Fintelmann FJ, Sequist LV, Donington J, Palmer JR, Yang CJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility. J Clin Oncol. 2024 Jun 10; 42(17):2026-2037.
journal title abbreviation: J Clin Oncol
publication date: 2024-03-27T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Professor of Medicine, Emeritus
is primary position: true
position in department: Emeritus
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Professor of Medicine, Emeritus
position in organization: Harvard Medical School

Authorship 1641038
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

Authorship 1641599
type: Authorship
author rank in publication: 25
linked author: Sequist, Lecia
linked information resource: Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
PubMed Identifier: 38591867
author list: Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT
published in: JCO precision oncology
information resource reference: Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 Apr; 8:e2300454.
journal title abbreviation: JCO Precis Oncol
publication date: 2024-04-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.
PubMed Identifier: 38559183
author list: Mishra A, Huang SB, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa Y, Kwak JE, Guay SY, Kelly J, Walsh J, Nieman L, Galler I, Chan P, Lawrence MS, Sullivan RJ, Bardia A, Micalizzi DS, Sequist LV, Lee RJ, Franses JW, Ting DT, Brunker PAR, Maheswaran S, Miyamoto DT, Haber DA, Toner M
published in: bioRxiv : the preprint server for biology
information resource reference: Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. bioRxiv. 2024 Mar 14.
journal title abbreviation: bioRxiv
publication date: 2024-03-14T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Early Detection and Interception of Lung Cancer.
PubMed Identifier: 38724286
author list: Chang AEB, Potter AL, Yang CJ, Sequist LV
published in: Hematology/oncology clinics of North America
information resource reference: Early Detection and Interception of Lung Cancer. Hematol Oncol Clin North Am. 2024 08; 38(4):755-770.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2024-05-08T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical Applications
end date: 2027-01-31
principal investigator name: HAAS, WILHELM
start date: 2024-02-12
type: Grant
sponsor award id: R61CA287026

Co-Principal Investigator
type: Researcher Role
researcher role of: Sequist, Lecia
contributes to: A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical Applications

Co-Principal Investigator
type: Researcher Role
researcher role of: Sequist, Lecia
contributes to: Dana Farber/Harvard Cancer Center SPORE in Lung Cancer

Authorship 1650098
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.

Authorship 1647491
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Early Detection and Interception of Lung Cancer.

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
PubMed Identifier: 38761385
author list: Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, Jänne PA, Mino-Kenudson M, Swanson S, Wright CD, Kozono D, Marcoux P, Piotrowska Z, Sequist LV, Willers H
published in: The oncologist
information resource reference: The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024 07 05; 29(7):609-618.
journal title abbreviation: Oncologist
publication date: 2024-07-05T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1656815
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.

Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.
PubMed Identifier: 38829053
author list: Mazzone PJ, Bach PB, Carey J, Schonewolf CA, Bognar K, Ahluwalia MS, Cruz-Correa M, Gierada D, Kotagiri S, Lloyd K, Maldonado F, Ortendahl JD, Sequist LV, Silvestri GA, Tanner N, Thompson JC, Vachani A, Wong KK, Zaidi AH, Catallini J, Gershman A, Lumbard K, Millberg LK, Nawrocki J, Portwood C, Rangnekar A, Sheridan CC, Trivedi N, Wu T, Zong Y, Cotton L, Ryan A, Cisar C, Leal A, Dracopoli N, Scharpf RB, Velculescu VE, Pike LRG
published in: Cancer discovery
information resource reference: Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection. Cancer Discov. 2024 Nov 01; 14(11):2224-2242.
journal title abbreviation: Cancer Discov
publication date: 2024-11-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1665652
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
PubMed Identifier: 38986421
author list: Felip E, Metro G, Soo RA, Wolf J, Solomon BJ, Tan DS, Ardizzoni A, Lee DH, Sequist LV, Barlesi F, Ponce-Aix S, Abreu DR, Campelo MRG, Sprauten M, Djentuh LO, Smith N, Jary A, Belli R, Glaser S, Zou M, Cui X, Giovannini M, Yang JC
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer. Eur J Cancer. 2024 Sep; 208:114182.
journal title abbreviation: Eur J Cancer
publication date: 2024-06-22T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 425465
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.

Authorship 241034
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.

Authorship 598959
type: Authorship
linked author: Sequist, Lecia
linked information resource: Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

Authorship 659537
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

Authorship 666802
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.

Authorship 655945
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Characteristics of lung cancers harboring NRAS mutations.

Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.
PubMed Identifier: 23399428
author list: Pirl WF, Traeger L, Greer JA, Jackson V, Lennes IT, Gallagher E, Sequist L, Temel JS
published in: Palliative & supportive care
information resource reference: Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer. Palliat Support Care. 2013 Jun; 11(3):223-9.
journal title abbreviation: Palliat Support Care
publication date: 2013-02-11T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Characteristics of lung cancers harboring NRAS mutations.
PubMed Identifier: 23515407
author list: Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 01; 19(9):2584-91.
journal title abbreviation: Clin Cancer Res
publication date: 2013-03-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
PubMed Identifier: 23553849
author list: Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
journal title abbreviation: Clin Cancer Res
publication date: 2013-04-03T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1702352
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Significance of Image Reconstruction Parameters for Future Lung Cancer Risk Prediction Using Low-Dose Chest Computed Tomography and the Open-Access Sybil Algorithm.

Authorship 1697645
type: Authorship
author rank in publication: 20
linked author: Sequist, Lecia
linked information resource: Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.

Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.
PubMed Identifier: 39406916
author list: Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, Sequist LV, Lennerz JK, Mino-Kenudson M, Maheswaran S, Naxerova K, Getz G, Haber DA
published in: Nature cancer
information resource reference: Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors. Nat Cancer. 2024 11; 5(11):1681-1696.
journal title abbreviation: Nat Cancer
publication date: 2024-10-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Significance of Image Reconstruction Parameters for Future Lung Cancer Risk Prediction Using Low-Dose Chest Computed Tomography and the Open-Access Sybil Algorithm.
PubMed Identifier: 39437009
author list: Simon J, Mikhael P, Graur A, Chang AEB, Skates SJ, Osarogiagbon RU, Sequist LV, Fintelmann FJ
published in: Investigative radiology
information resource reference: Significance of Image Reconstruction Parameters for Future Lung Cancer Risk Prediction Using Low-Dose Chest Computed Tomography and the Open-Access Sybil Algorithm. Invest Radiol. 2025 May 01; 60(5):311-318.
journal title abbreviation: Invest Radiol
publication date: 2024-10-23T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.
PubMed Identifier: 39577475
author list: Keane FK, Yeap BY, Khandekar MJ, Lin JJ, Dagogo-Jack I, Sequist LV, Piotrowska Z, Willers H
published in: International journal of radiation oncology, biology, physics
information resource reference: Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors. Int J Radiat Oncol Biol Phys. 2025 Mar 15; 121(4):975-979.
journal title abbreviation: Int J Radiat Oncol Biol Phys
publication date: 2024-11-20T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1708017
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.

Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.
PubMed Identifier: 39615410
author list: Dagogo-Jack I, Cooper AJ, Johnson BE, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Digumarthy SR, Mino-Kenudson M, Muzikansky A, Shaw AT
published in: Lung cancer (Amsterdam, Netherlands)
information resource reference: Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study. Lung Cancer. 2025 Jan; 199:108003.
journal title abbreviation: Lung Cancer
publication date: 2024-11-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1710272
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.
PubMed Identifier: 39746954
author list: Mishra A, Huang SB, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa Y, Kwak JE, Guay SY, Kelly J, Walsh J, Nieman LT, Galler I, Chan P, Lawrence MS, Sullivan RJ, Bardia A, Micalizzi DS, Sequist LV, Lee RJ, Franses JW, Ting DT, Brunker PAR, Maheswaran S, Miyamoto DT, Haber DA, Toner M
published in: Nature communications
information resource reference: Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Nat Commun. 2025 01 02; 16(1):32.
journal title abbreviation: Nat Commun
publication date: 2025-01-02T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1717218
type: Authorship
author rank in publication: 25
linked author: Sequist, Lecia
linked information resource: Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.

GUK1 activation is a metabolic liability in lung cancer.
PubMed Identifier: 39919745
author list: Schneider JL, Kurmi K, Dai Y, Dhiman I, Joshi S, Gassaway BM, Johnson CW, Jones N, Li Z, Joschko CP, Fujino T, Paulo JA, Yoda S, Baquer G, Ruiz D, Stopka SA, Kelley L, Do A, Mino-Kenudson M, Sequist LV, Lin JJ, Agar NYR, Gygi SP, Haigis KM, Hata AN, Haigis MC
published in: Cell
information resource reference: GUK1 activation is a metabolic liability in lung cancer. Cell. 2025 Mar 06; 188(5):1248-1264.e23.
journal title abbreviation: Cell
publication date: 2025-02-06T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 676426
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.

The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
PubMed Identifier: 23932319
author list: Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M
published in: The Annals of thoracic surgery
information resource reference: The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg. 2013 Sep; 96(3):962-8.
journal title abbreviation: Ann Thorac Surg
publication date: 2013-08-08T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Hematology/Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Massachusetts General Hospital

Authorship 259953
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Update on epidermal growth factor receptor inhibitor development in lung cancer.

Authorship 680672
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Authorship 679197
type: Authorship
author rank in publication: 12
linked author: Sequist, Lecia
linked information resource: Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Authorship 679729
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
PubMed Identifier: 23816960
author list: Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3327-34.
journal title abbreviation: J Clin Oncol
publication date: 2013-07-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
PubMed Identifier: 23816967
author list: Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3342-50.
journal title abbreviation: J Clin Oncol
publication date: 2013-07-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
PubMed Identifier: 23966292
author list: Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H
published in: Cancer research
information resource reference: EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013 Oct 15; 73(20):6254-63.
journal title abbreviation: Cancer Res
publication date: 2013-08-21T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 27917
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Detection of mutations in EGFR in circulating lung-cancer cells.

Authorship 28338
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

Authorship 340530
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authorship 1734422
type: Authorship
author rank in publication: 20
linked author: Sequist, Lecia
linked information resource: GUK1 activation is a metabolic liability in lung cancer.

Authorship 1736703
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.
PubMed Identifier: 40014838
author list: Leighl NB, Ismaila N, Durm G, Florez N, Freeman-Daily J, Pellini B, Mishra DR, Schenk EL, Sequist L, Singh N, Bazhenova L
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3. J Clin Oncol. 2025 04; 43(10):e17-e30.
journal title abbreviation: J Clin Oncol
publication date: 2025-02-27T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 692280
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
PubMed Identifier: 24072220
author list: Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV
published in: The oncologist
information resource reference: Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist. 2013; 18(11):1214-20.
journal title abbreviation: Oncologist
publication date: 2013-09-26T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Professor of Radiology, Emeritus
is primary position: true
position in department: Emeritus
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Professor of Radiology, Emeritus
position in organization: Harvard Medical School

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Hematology/Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Massachusetts General Hospital

Authorship 1738685
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US.

Authorship 1741268
type: Authorship
author rank in publication: 41
linked author: Sequist, Lecia
linked information resource: An ultrasensitive method for detection of cell-free RNA.

An ultrasensitive method for detection of cell-free RNA.
PubMed Identifier: 40240612
author list: Nesselbush MC, Luca BA, Jeon YJ, Jabara I, Meador CB, Garofalo A, Binkley MS, Hui AB, van 't Erve I, Xu N, Shi WY, Liu KJ, Sugio T, Kastelowitz N, Hamilton EG, Liu CL, Olsen M, Bonilla RF, Wang YP, Jiang A, Lau B, Eichholz J, Banwait M, Schroers-Martin J, Boegeholz J, King DA, Luikart H, Esfahani MS, Mehrmohamadi M, Stehr H, Raclin T, Tibshirani R, Khush K, Srinivas S, Yu H, Rogers AJ, Nair VS, Isbell JM, Li BT, Piotrowska Z, Sequist LV, Hata AN, Neal JW, Wakelee HA, Gentles AJ, Alizadeh AA, Diehn M
published in: Nature
information resource reference: An ultrasensitive method for detection of cell-free RNA. Nature. 2025 05; 641(8063):759-768.
journal title abbreviation: Nature
publication date: 2025-04-16T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US.
PubMed Identifier: 40172870
author list: Potter AL, Kothagundla S, Haridas C, Chang AEB, Sequist LV, Yang CJ
published in: JAMA
information resource reference: Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US. JAMA. 2025 May 13; 333(18):1635-1638.
journal title abbreviation: JAMA
publication date: 2025-05-13T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 699095
type: Authorship
author rank in publication: 16
linked author: Sequist, Lecia
linked information resource: Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
PubMed Identifier: 24353160
author list: Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB
published in: Science translational medicine
information resource reference: Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177.
journal title abbreviation: Sci Transl Med
publication date: 2013-12-18T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 195461
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.

Authorship 293144
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: A new BATTLE in the evolving war on cancer.

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Hematology/Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Massachusetts General Hospital

Authorship 714664
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Reply to E.R. Haspinger et al.

Authorship 718383
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Reply to F. De Marinis et al.

Authorship 711266
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
PubMed Identifier: 23649446
author list: Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE
published in: Chest
information resource reference: Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May; 143(5 Suppl):e341S-e368S.
journal title abbreviation: Chest
publication date: 2013-05-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Reply to E.R. Haspinger et al.
PubMed Identifier: 24493734
author list: Yang JC, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Reply to E.R. Haspinger et al. J Clin Oncol. 2014 Mar 10; 32(8):863-4.
journal title abbreviation: J Clin Oncol
publication date: 2014-02-03T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Reply to F. De Marinis et al.
PubMed Identifier: 24493733
author list: Yang JC, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Reply to F. De Marinis et al. J Clin Oncol. 2014 Mar 10; 32(8):865.
journal title abbreviation: J Clin Oncol
publication date: 2014-02-03T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 337503
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

Professor of Radiology
is primary position: true
position in department: Radiology
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Professor of Radiology
position in organization: Massachusetts General Hospital

George P. Canellos, MD, and Jean S. Canellos Professor of Medicine Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: George P. Canellos, MD, and Jean S. Canellos Professor of Medicine Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: DF Thoracic Onc
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Beth Israel Deaconess Medical Center

DF Thoracic Onc
type: Division
type: Organization

Authorship 729296
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Isolation and molecular characterization of circulating melanoma cells.

Authorship 729280
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
PubMed Identifier: 24846037
author list: Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA
published in: JAMA
information resource reference: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006.
journal title abbreviation: JAMA
publication date: 2014-05-21T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Isolation and molecular characterization of circulating melanoma cells.
PubMed Identifier: 24746818
author list: Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA
published in: Cell reports
information resource reference: Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 08; 7(3):645-53.
journal title abbreviation: Cell Rep
publication date: 2014-04-18T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 272570
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.

Authorship 1792186
type: Authorship
author rank in publication: 32
linked author: Sequist, Lecia
linked information resource: Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.

Authorship 1817967
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/323045531

Authorship 1822366
type: Authorship
author rank in publication: 26
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/323037066

Authorship 1826042
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Blended palliative and survivorship care intervention (POISE) for patients with metastatic oncogene-driven non-small cell lung cancer: study protocol for a pilot randomised controlled trial.

Authorship 1832197
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Lung Cancer Screening Saves Lives, but Could Save So Many More.

Authorship 1831631
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.

Authorship 1835786
type: Authorship
author rank in publication: 30
linked author: Sequist, Lecia
linked information resource: Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Authorship 1835784
type: Authorship
author rank in publication: 30
linked author: Sequist, Lecia
linked information resource: Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.

COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.
PubMed Identifier: 41139117
author list: Peled N, Tufman A, Sequist LV, Pasello G, Wang Q, Antonuzzo L, González Larriba J, Medina Valdivieso S, Cobo Dols M, Milella M, Dudnik J, Martín-Martorell P, Barneto Aranda I, Huang D, Palicio NV, Scimone A, Bria E, Servidio L, Pimentel R, Ganiyu AA, Zhao J
published in: ESMO open
information resource reference: COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib. ESMO Open. 2025 Oct; 10(10):105807.
journal title abbreviation: ESMO Open
publication date: 2025-09-08T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.
PubMed Identifier: 40762432
author list: Baldacci S, Brea EJ, Facchinetti F, Li Z, Ngo K, Malhotra S, Booker MA, Tolstorukov MY, Chakravarti S, Hinchey C, Mahadevan NR, Lococo F, D'Agnelli S, Gnetti L, Campanini N, Leonetti A, Feng WW, Tsai JA, Hartley AV, Locquet MA, Fournel L, Alifano M, Mansuet-Lupo A, Saldanha A, Haller W, Zasadil LM, Zielinska M, Bui K, Tuladhar B, Lizotte PH, Ivanova EV, Sequist LV, Gokhale PC, Paweletz CP, Smith EL, Jänne PA, Barbie DA
published in: Cancer discovery
information resource reference: Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy. Cancer Discov. 2025 Nov 03; 15(11):2235-2250.
journal title abbreviation: Cancer Discov
publication date: 2025-11-03T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Blended palliative and survivorship care intervention (POISE) for patients with metastatic oncogene-driven non-small cell lung cancer: study protocol for a pilot randomised controlled trial.
PubMed Identifier: 40812801
author list: Richard HA, Sarathy R, Rabideau DJ, Feldman J, Cartagena L, Patel H, Sequist LV, Park E, Jackson V, Greer JA, Temel JS, Petrillo LA
published in: BMJ open
information resource reference: Blended palliative and survivorship care intervention (POISE) for patients with metastatic oncogene-driven non-small cell lung cancer: study protocol for a pilot randomised controlled trial. BMJ Open. 2025 Aug 13; 15(8):e098075.
journal title abbreviation: BMJ Open
publication date: 2025-08-13T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Lung Cancer Screening Saves Lives, but Could Save So Many More.
PubMed Identifier: 41259198
author list: Potter AL, Sequist LV, Yang CJ
published in: JAMA
information resource reference: Lung Cancer Screening Saves Lives, but Could Save So Many More. JAMA. 2025 Dec 23; 334(24):2174-2175.
journal title abbreviation: JAMA
publication date: 2025-12-23T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/323037066
PubMed Identifier: 40461383
author list: de Marinis F, Kim TM, Bonanno L, Cheng S, Kim SW, Tiseo M, Chu Q, Proto C, Sacher A, Luo YH, Novello S, Hao D, Baik C, Bazhenova L, Lee JS, Cho BC, Cadranel J, Diep TB, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeño J, Baldotto C, Nyhus C, Yang JC, Sequist LV, Levy B, Hartmaier R, Igwegbe I, Poole L, Xu W, Ahn MJ
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. Ann Oncol. 2025 Aug; 36(8):920-933.
journal title abbreviation: Ann Oncol
publication date: 2025-06-02T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.
PubMed Identifier: 41632926
author list: Puri S, Leighl NB, Ismaila N, Rous FA, Ahluwalia A, Alluri K, Azar IH, Campbell T, Durm G, Feldman J, Florez N, Freeman-Daily J, Furuya N, Gadgeel S, Halmos B, Horinouchi H, Kuruvilla S, Macvicar GR, Malhotra N, Marrone KA, Mishra DR, Mullane M, Naidoo J, Owen DH, Pellini B, Presley CJ, Qin A, Roof L, Schenk EL, Sequist L, Singh N, Singhi EK, Suga JM, Velazquez AI, Wang Y, Price PW, Reuss JE, Bazhenova L
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0. J Clin Oncol. 2026 Mar; 44(7):e15-e55.
journal title abbreviation: J Clin Oncol
publication date: 2026-02-03T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.
PubMed Identifier: 41632927
author list: Reuss JE, Bazhenova L, Ismaila N, Abu Rous F, Ahluwalia A, Alluri K, Azar IH, Campbell T, Durm G, Feldman J, Florez N, Freeman-Daily J, Furuya N, Gadgeel S, Halmos B, Horinouchi H, Kuruvilla S, Macvicar GR, Malhotra N, Marrone KA, Mishra DR, Mullane M, Naidoo J, Owen DH, Pellini B, Presley CJ, Qin A, Roof L, Schenk EL, Sequist L, Singh N, Singhi EK, Suga JM, Velazquez AI, Wang Y, Wheatley Price P, Puri S, Leighl NB
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0. J Clin Oncol. 2026 Mar; 44(7):e56-e88.
journal title abbreviation: J Clin Oncol
publication date: 2026-02-03T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/323045531
PubMed Identifier: 41567301
author list: Behera M, Joseph G, Rupji M, Huang Z, Bunn B, Wynes MW, Switchenko J, Scagliotti GV, Tsao MS, Belani CP, Sequist LV, Ramalingam SS
published in: JTO clinical and research reports
information resource reference: Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data. JTO Clin Res Rep. 2026 Feb; 7(2):100816.
journal title abbreviation: JTO Clin Res Rep
publication date: 2025-02-28T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data.

Authorship 737954
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Circulating tumour cells-monitoring treatment response in prostate cancer.

Circulating tumour cells-monitoring treatment response in prostate cancer.
PubMed Identifier: 24821215
author list: Miyamoto DT, Sequist LV, Lee RJ
published in: Nature reviews. Clinical oncology
information resource reference: Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol. 2014 Jul; 11(7):401-12.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2014-05-13T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 33796
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Detection of impaired homologous recombination repair in NSCLC cells and tissues.

Authorship 348397
type: Authorship
author rank in publication: 22
linked author: Sequist, Lecia
linked information resource: Lung cancer screening.

Elkan Blout Professor of Environmental Genetics
is primary position: true
position in department: Environmental Health
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Elkan Blout Professor of Environmental Genetics
position in organization: Harvard T.H. Chan School of Public Health

Brain tumor cells in circulation are enriched for mesenchymal gene expression.
PubMed Identifier: 25139148
author list: Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA
published in: Cancer discovery
information resource reference: Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.
journal title abbreviation: Cancer Discov
publication date: 2014-08-19T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 749261
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Acquired resistance to TKIs in solid tumours: learning from lung cancer.
PubMed Identifier: 24981256
author list: Camidge DR, Pao W, Sequist LV
published in: Nature reviews. Clinical oncology
information resource reference: Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014 Aug; 11(8):473-81.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2014-07-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 395275
type: Authorship
author rank in publication: 19
linked author: Sequist, Lecia
linked information resource: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Authorship 765177
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Genotyping lung cancer is an investment in the future.

Genotyping lung cancer is an investment in the future.
PubMed Identifier: 25199750
author list: Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Genotyping lung cancer is an investment in the future. J Clin Oncol. 2014 Nov 01; 32(31):3576-7.
journal title abbreviation: J Clin Oncol
publication date: 2014-09-08T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 768044
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Brain tumor cells in circulation are enriched for mesenchymal gene expression.

Authorship 483849
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Authorship 421810
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Molecular analysis-based treatment strategies for the management of non-small cell lung cancer.

Authorship 24286
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
PubMed Identifier: 25394791
author list: Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, Awad MM, Ramaswamy S, Mino-Kenudson M, Iafrate AJ, Benes CH, Engelman JA
published in: Science (New York, N.Y.)
information resource reference: Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014 Dec 19; 346(6216):1480-6.
journal title abbreviation: Science
publication date: 2014-11-13T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 504929
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

Authorship 776076
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Authorship 544430
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Authorship 778493
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/36809520

Authorship 778114
type: Authorship
author rank in publication: 15
linked author: Sequist, Lecia
linked information resource: Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

https://connects.catalyst.harvard.edu/Profiles/profile/36809520
PubMed Identifier: 25452446
author list: Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol. 2015 Jan 10; 33(2):189-94.
journal title abbreviation: J Clin Oncol
publication date: 2014-12-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
PubMed Identifier: 25535693
author list: Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
journal title abbreviation: J Thorac Oncol
publication date: 2015-01-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 575159
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

Authorship 517554
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: ROS1-targeted therapy in non-small cell lung cancer.

Authorship 402195
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
PubMed Identifier: 25758528
author list: Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA
published in: Nature communications
information resource reference: RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015 Mar 11; 6:6377.
journal title abbreviation: Nat Commun
publication date: 2015-03-11T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
PubMed Identifier: 25759424
author list: Arvold ND, Heidari P, Kunawudhi A, Sequist LV, Mahmood U
published in: Technology in cancer research & treatment
information resource reference: Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET. Technol Cancer Res Treat. 2016 Apr; 15(2):234-42.
journal title abbreviation: Technol Cancer Res Treat
publication date: 2015-03-10T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells.
PubMed Identifier: 25640006
author list: Reátegui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist LV, Haber DA, Maheswaran S, Hammond PT, Toner M, Stott SL
published in: Advanced materials (Deerfield Beach, Fla.)
information resource reference: Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater. 2015 Mar 04; 27(9):1593-9.
journal title abbreviation: Adv Mater
publication date: 2015-01-15T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 87573
type: Authorship
author rank in publication: 25
linked author: Sequist, Lecia
linked information resource: Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.

Authorship 41233
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authorship 175845
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Authorship 475941
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Genetic changes in squamous cell lung cancer: a review.

Authorship 603909
type: Authorship
linked author: Sequist, Lecia
linked information resource: Non-small cell lung cancer

Authorship 227661
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authorship 431265
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.

Authorship 540835
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.

Authorship 64626
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.

Authorship 262748
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: FGFR1 amplification in squamous cell carcinoma of the lung.

Authorship 248710
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Authorship 233894
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

Authorship 12005
type: Authorship
author rank in publication: 17
linked author: Sequist, Lecia
linked information resource: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authorship 356118
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Protein degradation/chaperone system and histone deacetylase pathway.

Authorship 251877
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

Authorship 346939
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.

Authorship 349435
type: Authorship
author rank in publication: 18
linked author: Sequist, Lecia
linked information resource: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis.

Authorship 410906
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Toward noninvasive genomic screening of lung cancer patients.

Authorship 364124
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.

Authorship 561978
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

Authorship 36193
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.

Authorship 376981
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.

Authorship 797618
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Authorship 801842
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

Authorship 802367
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: The anticipated next season of EGFR inhibitors.

Authorship 802231
type: Authorship
author rank in publication: 26
linked author: Sequist, Lecia
linked information resource: Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.

Authorship 788775
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.

Authorship 790071
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Authorship 793087
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authorship 804277
type: Authorship
author rank in publication: 12
linked author: Sequist, Lecia
linked information resource: Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells.

Authorship 806286
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.

Authorship 801512
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Lipodermatosclerosis secondary to pemetrexed use.

Authorship 790888
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer.

Authorship 800950
type: Authorship
author rank in publication: 28
linked author: Sequist, Lecia
linked information resource: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authorship 803234
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Lipodermatosclerosis secondary to pemetrexed use.
PubMed Identifier: 25695225
author list: Shuster M, Morley K, Logan J, Sequist LV, Shaw A, Fidias P, Kroshinsky D
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Lipodermatosclerosis secondary to pemetrexed use. J Thorac Oncol. 2015 Mar; 10(3):e11-2.
journal title abbreviation: J Thorac Oncol
publication date: 2015-03-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.
PubMed Identifier: 25806260
author list: Neal JW, Sequist LV
published in: Translational lung cancer research
information resource reference: Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. Transl Lung Cancer Res. 2013 Oct; 2(5):411-4.
journal title abbreviation: Transl Lung Cancer Res
publication date: 2013-10-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.
PubMed Identifier: 25583767
author list: Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Leung AN, Makani SS, Massion PP, Meyers BF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Sequist LV, Tong BC, Travis WD, Yang SC, Gregory KM, Hughes M
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2015 Jan; 13(1):23-34; quiz 34.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2015-01-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Rociletinib in EGFR-mutated non-small-cell lung cancer.
PubMed Identifier: 25923550
author list: Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR
published in: The New England journal of medicine
information resource reference: Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9.
journal title abbreviation: N Engl J Med
publication date: 2015-04-30T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

The anticipated next season of EGFR inhibitors.
PubMed Identifier: 25795633
author list: Sequist LV
published in: The oncologist
information resource reference: The anticipated next season of EGFR inhibitors. Oncologist. 2015 Apr; 20(4):335-6.
journal title abbreviation: Oncologist
publication date: 2015-03-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
PubMed Identifier: 25589191
author list: Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV
published in: The Lancet. Oncology
information resource reference: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb; 16(2):141-51.
journal title abbreviation: Lancet Oncol
publication date: 2015-01-12T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
PubMed Identifier: 25846096
author list: Oser MG, Niederst MJ, Sequist LV, Engelman JA
published in: The Lancet. Oncology
information resource reference: Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015 Apr; 16(4):e165-72.
journal title abbreviation: Lancet Oncol
publication date: 2015-04-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer.
PubMed Identifier: 26017825
author list: Kamdar MM, Doyle KP, Sequist LV, Rinehart TJ, Maytal G, Flores EJ, Mino-Kenudson M
published in: The New England journal of medicine
information resource reference: Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer. N Engl J Med. 2015 May 28; 372(22):2137-47.
journal title abbreviation: N Engl J Med
publication date: 2015-05-28T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
PubMed Identifier: 25273224
author list: Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG
published in: Cancer
information resource reference: Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015 Feb 01; 121(3):448-56.
journal title abbreviation: Cancer
publication date: 2014-10-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
PubMed Identifier: 25605928
author list: Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):1547-52.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2015-01-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
PubMed Identifier: 25053852
author list: Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, Loeffler JS, Sequist LV, Shaw AT, Shih HA
published in: Neuro-oncology
information resource reference: Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015 Feb; 17(2):296-302.
journal title abbreviation: Neuro Oncol
publication date: 2014-07-22T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 613239
type: Authorship
linked author: Sequist, Lecia
linked information resource: The effects of betamethasone and dexamethasone on blood pressure, heart rate, and heart rate variation in fetal sheep

Authorship 246285
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Treatment of advanced non-small cell lung cancer in the elderly.

Authorship 247494
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.

Authorship 363716
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.

Authorship 539297
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Authorship 811958
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
PubMed Identifier: 25897158
author list: Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-12.
journal title abbreviation: J Clin Oncol
publication date: 2015-04-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 284916
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.

Authorship 814856
type: Authorship
author rank in publication: 23
linked author: Sequist, Lecia
linked information resource: Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Authorship 814824
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

Authorship 814763
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
PubMed Identifier: 25934077
author list: Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV
published in: Cancer discovery
information resource reference: Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015 Jul; 5(7):713-22.
journal title abbreviation: Cancer Discov
publication date: 2015-05-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
PubMed Identifier: 26051236
author list: Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL
published in: The Lancet. Oncology
information resource reference: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul; 16(7):830-8.
journal title abbreviation: Lancet Oncol
publication date: 2015-06-04T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.
PubMed Identifier: 26149875
author list: Engelman JA, Oser MG, Niederst MJ, Sequist LV
published in: The Lancet. Oncology
information resource reference: Transformation from NSCLC to SCLC: when did it happen? - Authors' reply. Lancet Oncol. 2015 Jul; 16(7):e309-10.
journal title abbreviation: Lancet Oncol
publication date: 2015-07-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 817486
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.

Authorship 817034
type: Authorship
author rank in publication: 9
linked author: Sequist, Lecia
linked information resource: Biodegradable nano-films for capture and non-invasive release of circulating tumor cells.

Biodegradable nano-films for capture and non-invasive release of circulating tumor cells.
PubMed Identifier: 26142780
author list: Li W, Reátegui E, Park MH, Castleberry S, Deng JZ, Hsu B, Mayner S, Jensen AE, Sequist LV, Maheswaran S, Haber DA, Toner M, Stott SL, Hammond PT
published in: Biomaterials
information resource reference: Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. Biomaterials. 2015 Oct; 65:93-102.
journal title abbreviation: Biomaterials
publication date: 2015-06-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
PubMed Identifier: 25876525
author list: Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, Jänne PA, Oxnard GR
published in: Cancer
information resource reference: Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7.
journal title abbreviation: Cancer
publication date: 2015-04-15T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 358800
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

Authorship 823136
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
PubMed Identifier: 26244318
author list: Sequist LV, Rolfe L, Allen AR
published in: The New England journal of medicine
information resource reference: Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2015 08 06; 373(6):578-9.
journal title abbreviation: N Engl J Med
publication date: 2015-08-06T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 824967
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/60683564

https://connects.catalyst.harvard.edu/Profiles/profile/60683564
PubMed Identifier: 26169611
author list: Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Aug 20; 33(24):2667-74.
journal title abbreviation: J Clin Oncol
publication date: 2015-07-13T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Authorship 830200
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
PubMed Identifier: 25964297
author list: Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res. 2015 Sep 01; 21(17):3924-33.
journal title abbreviation: Clin Cancer Res
publication date: 2015-05-11T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 614285
type: Authorship
linked author: Sequist, Lecia
linked information resource: Chapter 22. Epidermal Growth Factor Receptor Inhibitors

Authorship 833252
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.

Authorship 834461
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.

Authorship 834501
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.

Authorship 833956
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
PubMed Identifier: 26352419
author list: Sequist LV
published in: Clinical advances in hematology & oncology : H&O
information resource reference: The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer. Clin Adv Hematol Oncol. 2015 Mar; 13(3):147-9.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2015-03-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.
PubMed Identifier: 26383955
author list: Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DA
published in: Science (New York, N.Y.)
information resource reference: RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015 Sep 18; 349(6254):1351-6.
journal title abbreviation: Science
publication date: 2015-09-18T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
PubMed Identifier: 26389761
author list: Piotrowska Z, Sequist LV
published in: Cancer journal (Sudbury, Mass.)
information resource reference: Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. Cancer J. 2015 Sep-Oct; 21(5):371-7.
journal title abbreviation: Cancer J
publication date: 2015-09-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
PubMed Identifier: 26189086
author list: Leung LS, Neal JW, Wakelee HA, Sequist LV, Marmor MF
published in: American journal of ophthalmology
information resource reference: Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. Am J Ophthalmol. 2015 Oct; 160(4):799-805.e1.
journal title abbreviation: Am J Ophthalmol
publication date: 2015-07-17T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 379531
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

Authorship 432039
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authorship 843588
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

Authorship 846120
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.
PubMed Identifier: 26313684
author list: Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. J Thorac Oncol. 2015 Nov; 10(11):1601-7.
journal title abbreviation: J Thorac Oncol
publication date: 2015-11-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
PubMed Identifier: 26500230
author list: Piotrowska Z, Sequist LV
published in: The oncologist
information resource reference: Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand? Oncologist. 2015 Nov; 20(11):1230-2.
journal title abbreviation: Oncologist
publication date: 2015-10-23T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 461817
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Authorship 455453
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors.

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
PubMed Identifier: 26776293
author list: Nishino M, Dahlberg SE, Fulton LE, Digumarthy SR, Hatabu H, Johnson BE, Sequist LV
published in: Academic radiology
information resource reference: Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar; 23(3):329-36.
journal title abbreviation: Acad Radiol
publication date: 2016-01-08T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 74703
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

Authorship 862866
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Authorship 865738
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.

Authorship 866875
type: Authorship
author rank in publication: 28
linked author: Sequist, Lecia
linked information resource: Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Authorship 867917
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
PubMed Identifier: 26828195
author list: Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA
published in: Nature medicine
information resource reference: Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016 Mar; 22(3):262-9.
journal title abbreviation: Nat Med
publication date: 2016-02-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
PubMed Identifier: 26823294
author list: Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016 Mar; 11(3):380-90.
journal title abbreviation: J Thorac Oncol
publication date: 2016-01-25T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
PubMed Identifier: 26446944
author list: Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res. 2016 Mar 01; 22(5):1103-10.
journal title abbreviation: Clin Cancer Res
publication date: 2015-10-07T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 604505
type: Authorship
linked author: Sequist, Lecia
linked information resource: Review of EGFR Inhibitors in Lung Cancer

Authorship 871920
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.

Authorship 358557
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authorship 877171
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.
PubMed Identifier: 26720284
author list: Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA
published in: JAMA oncology
information resource reference: Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. JAMA Oncol. 2016 Apr; 2(4):541-3.
journal title abbreviation: JAMA Oncol
publication date: 2016-04-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 881428
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).

Authorship 880793
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/65024405

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
PubMed Identifier: 26747242
author list: Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clin Cancer Res. 2016 05 15; 22(10):2386-95.
journal title abbreviation: Clin Cancer Res
publication date: 2016-01-08T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/65024405
PubMed Identifier: 27198276
author list: Schuler M, Yang J, Sequist LV, Yamamoto N, Zhou C, O'Byrne K, Hirsh V, Mok T, Shah R, Wu YL
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). J Thorac Oncol. 2016 Apr; 11(4 Suppl):S116-7.
journal title abbreviation: J Thorac Oncol
publication date: 2016-04-15T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource
label: 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6).

Authorship 885866
type: Authorship
author rank in publication: 17
linked author: Sequist, Lecia
linked information resource: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Authorship 886141
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Update to Rociletinib Data with the RECIST Confirmed Response Rate.

Update to Rociletinib Data with the RECIST Confirmed Response Rate.
PubMed Identifier: 27195670
author list: Sequist LV, Soria JC, Camidge DR
published in: The New England journal of medicine
information resource reference: Update to Rociletinib Data with the RECIST Confirmed Response Rate. N Engl J Med. 2016 Jun 09; 374(23):2296-7.
journal title abbreviation: N Engl J Med
publication date: 2016-05-11T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
PubMed Identifier: 27283993
author list: Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M
published in: Nature communications
information resource reference: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 06 10; 7:11815.
journal title abbreviation: Nat Commun
publication date: 2016-06-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 588667
type: Authorship
linked author: Sequist, Lecia
linked information resource: HER2 amplification as a biomarker in non-small cell lung cancer

Authorship 94992
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

Authorship 888631
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
PubMed Identifier: 26988570
author list: Gainor JF, Niederst MJ, Lennerz JK, Dagogo-Jack I, Stevens S, Shaw AT, Sequist LV, Engelman JA
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. J Thorac Oncol. 2016 07; 11(7):e83-5.
journal title abbreviation: J Thorac Oncol
publication date: 2016-03-14T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Assistant Professor
sort order: 2
type: Faculty Rank

Associate Professor
sort order: 1
type: Faculty Rank

Full Professor
sort order: 0
type: Faculty Rank

Authorship 890638
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.

Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.
PubMed Identifier: 27196961
author list: Piotrowska Z, Sequist LV
published in: JAMA oncology
information resource reference: Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review. JAMA Oncol. 2016 Jul 01; 2(7):948-54.
journal title abbreviation: JAMA Oncol
publication date: 2016-07-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 894979
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

Authorship 894590
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
PubMed Identifier: 27343442
author list: Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 08; 11(8):1242-1245.
journal title abbreviation: J Thorac Oncol
publication date: 2016-06-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.
PubMed Identifier: 27079185
author list: Piotrowska Z, Drapkin B, Engelman JA, Nagy RJ, Lanman RB, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer. J Thorac Oncol. 2016 08; 11(8):e95-e97.
journal title abbreviation: J Thorac Oncol
publication date: 2016-04-12T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 897109
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
PubMed Identifier: 27354669
author list: Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H
published in: The oncologist
information resource reference: Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist. 2016 08; 21(8):964-73.
journal title abbreviation: Oncologist
publication date: 2016-06-27T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
PubMed Identifier: 27544060
author list: Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, Shaw AT, Gainor JF
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 11; 11(11):2027-2032.
journal title abbreviation: J Thorac Oncol
publication date: 2016-08-17T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 910815
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.
PubMed Identifier: 27296107
author list: Dagogo-Jack I, Gainor JF, Porter RL, Schultz KR, Solomon BJ, Stevens S, Azzoli CG, Sequist LV, Lennes IT, Shaw AT
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. J Thorac Oncol. 2016 09; 11(9):1522-8.
journal title abbreviation: J Thorac Oncol
publication date: 2016-06-11T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Training Program in Cancer Biology and Therapeutics
end date: 2028-06-30
principal investigator name: HABER, DANIEL A.
start date: 1997-08-01
type: Grant
sponsor award id: T32CA071345

Non-genomic resistance mechanisms in EGFR-mutant lung cancer
end date: 2027-05-31
principal investigator name: HATA, AARON N
start date: 2009-03-01
type: Grant
sponsor award id: R01CA137008

Repeat Biopsies in Lung Cancer to Define Targeted Resistance Mechanisms
end date: 2013-04-30
principal investigator name: SEQUIST, LECIA V.
start date: 2011-05-01
type: Grant
sponsor award id: R21CA156000

Co-Principal Investigator
type: Researcher Role
researcher role of: Sequist, Lecia
contributes to: Non-genomic resistance mechanisms in EGFR-mutant lung cancer

Principal Investigator
type: Researcher Role
researcher role of: Sequist, Lecia
contributes to: Repeat Biopsies in Lung Cancer to Define Targeted Resistance Mechanisms

Authorship 915463
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
PubMed Identifier: 27225694
author list: Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016 Sep 15; 22(18):4585-93.
journal title abbreviation: Clin Cancer Res
publication date: 2016-05-25T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 918096
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
PubMed Identifier: 27468937
author list: Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016 Oct; 11(10):1690-700.
journal title abbreviation: J Thorac Oncol
publication date: 2016-07-25T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 920038
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review.

Authorship 921739
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

Authorship 923179
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.

Authorship 928202
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authorship 925944
type: Authorship
author rank in publication: 28
linked author: Sequist, Lecia
linked information resource: Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.
PubMed Identifier: 27553514
author list: Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, Muzikansky A, Engelman JA, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016 11; 11(11):2022-2026.
journal title abbreviation: J Thorac Oncol
publication date: 2016-08-20T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review.
PubMed Identifier: 27464969
author list: Pareek V, Welch M, Ravera E, Zampolin RL, Sequist LV, Halmos B
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review. J Thorac Oncol. 2016 11; 11(11):e135-e139.
journal title abbreviation: J Thorac Oncol
publication date: 2016-07-25T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
PubMed Identifier: 27432227
author list: Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT
published in: Cancer discovery
information resource reference: Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
journal title abbreviation: Cancer Discov
publication date: 2016-07-18T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
PubMed Identifier: 27745820
author list: Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L
published in: The Lancet. Oncology
information resource reference: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508.
journal title abbreviation: Lancet Oncol
publication date: 2016-10-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 445513
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Authorship 931569
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Authorship 934725
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/70167519

Authorship 933528
type: Authorship
author rank in publication: 17
linked author: Sequist, Lecia
linked information resource: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

https://connects.catalyst.harvard.edu/Profiles/profile/70167519
PubMed Identifier: 27870574
author list: Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017 Jan 10; 35(2):157-165.
journal title abbreviation: J Clin Oncol
publication date: 2016-11-21T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
PubMed Identifier: 27841271
author list: Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M
published in: Nature communications
information resource reference: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 11 14; 7:13513.
journal title abbreviation: Nat Commun
publication date: 2016-11-14T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
PubMed Identifier: 27601237
author list: Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Märten A, Massey D, Wind S, Wu YL
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016 11; 27(11):2103-2110.
journal title abbreviation: Ann Oncol
publication date: 2016-09-06T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 597029
type: Authorship
linked author: Sequist, Lecia
linked information resource: Risk stratification for elderly patients: Assessing who should be treated

Authorship 599225
type: Authorship
linked author: Sequist, Lecia
linked information resource: Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status.

Authorship 941281
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts).

Authorship 941744
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71516891

Authorship 944242
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

Authorship 943980
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71516542

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
PubMed Identifier: 28006816
author list: Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, Kim M, Yang JC
published in: British journal of cancer
information resource reference: EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017 Jan 17; 116(2):175-185.
journal title abbreviation: Br J Cancer
publication date: 2016-12-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts).
PubMed Identifier: 27953740
author list: Sequist LV, Joshi VA, Jänne PA, Fidias P, Muzikansky A, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2006 Jun 20; 24(18_suppl):7177.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71516542
PubMed Identifier: 27937470
author list: Schiller JH, Akerley WL, Brugger W, Ferrari D, Garmey EG, Gerber DE, Orlov SV, Ramlau R, Von Pawel J, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2010 Jun 20; 28(18_suppl):LBA7502.
journal title abbreviation: J Clin Oncol
publication date: 2010-06-20T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

https://connects.catalyst.harvard.edu/Profiles/profile/71516891
PubMed Identifier: 27962649
author list: Sequist LV, Gettinger S, Natale R, Martins R, Lilenbaum R, Jänne P, Gray J, Samuel TA, Grayzel D, Lynch TJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J Clin Oncol. 2009 May 20; 27(15_suppl):8073.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource
label: A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status.

Authorship 945040
type: Authorship
author rank in publication: 10
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71645977

Authorship 944469
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).

Authorship 944459
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.

Authorship 945529
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71645765

Authorship 944525
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.

Authorship 944394
type: Authorship
author rank in publication: 6
linked author: Sequist, Lecia
linked information resource: Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC.

https://connects.catalyst.harvard.edu/Profiles/profile/71645765
PubMed Identifier: 28023476
author list: Sandler A, Schiller JH, Hirsh V, Sequist LV, Soria J, Von Pawel J, Wang Q, Pande AU, Schwartz BE, Garmey EG, Gorbatchevsky I, Scagliotti G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) . J Clin Oncol. 2011 May 20; 29(15_suppl):TPS217.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .

Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC.
PubMed Identifier: 28020106
author list: Heist RS, Duda GD, Sahani D, Ancukiewicz M, Fidias P, Sequist LV, Shaw AT, Temel JS, Lennes IT, Neal JW, Pennell NA, Lynch TJ, Engelman JA, Jain RK
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. J Clin Oncol. 2011 May 20; 29(15_suppl):e18016.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71645977
PubMed Identifier: 28023496
author list: Pennell NA, Neal JW, Govindan R, Janne PA, Evans TL, Costa DB, Rosovsky RP, Lanuti M, Azzoli CG, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS209.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).

SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.
PubMed Identifier: 28023280
author list: Sequist LV, Heist RS, Shaw AT, Fidias P, Temel JS, Lennes IT, Bast E, Waltman BA, Lanuti M, Muzikansky A, Mino-Kenudson M, Iafrate AJ, Borger DR, Dias-Santagata D, Engelman JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
PubMed Identifier: 28023478
author list: Sequist LV, Harb WA, Modiano M, Jackman DM, Wong K, Engelman JA, Nering R, Onsum M, Moyo VM
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS215.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
PubMed Identifier: 28023484
author list: Therasse P, Vansteenkiste JF, Zielinski M, De Pas TM, Atanackovic D, Sequist LV, Vallieres E, Swisher S, Adams S, Passlick B, Eberhardt WE, Grunenwald D, Mok T, Boyer M, Katz A, Douillard J, Debois M, Brichard VG, Altorki NK
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS210.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.
PubMed Identifier: 28096363
author list: Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, Haber DA
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1123-1128.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2017-01-17T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 950976
type: Authorship
author rank in publication: 17
linked author: Sequist, Lecia
linked information resource: An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.

Authorship 955290
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations.

Authorship 954298
type: Authorship
author rank in publication: 19
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/72396592

Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations.
PubMed Identifier: 28142731
author list: Piotrowska Z, Scribner E, Temel B, Heist RS, Sequist LV, Temel JS
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations. J Clin Oncol. 2014 Nov; 32(31_suppl):126.
journal title abbreviation: J Clin Oncol
publication date: 2014-11-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/72396592
PubMed Identifier: 28140812
author list: Schuler MH, Yamamoto N, O'Byrne KJ, Hirsh V, Mok T, Geater SL, Orlov SV, Tsai CM, Boyer MJ, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah RN, Massey D, Lorence RM, Shahidi M, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol. 2012 Jun 20; 30(18_suppl):LBA7500.
journal title abbreviation: J Clin Oncol
publication date: 2012-06-20T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Authorship 63023
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: Epidermal growth factor receptor tyrosine kinase inhibitors and depression.

Authorship 958669
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Authorship 958210
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
PubMed Identifier: 28221867
author list: Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20; 35(12):1288-1296.
journal title abbreviation: J Clin Oncol
publication date: 2017-02-21T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.
PubMed Identifier: 28215720
author list: Piotrowska Z, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2017 03; 12(3):419-421.
journal title abbreviation: J Thorac Oncol
publication date: 2017-03-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Expression of ß-globin by cancer cells promotes cell survival during blood-borne dissemination.
PubMed Identifier: 28181495
author list: Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, Yu M, Karabacak NM, Comaills V, Morris R, Desai R, Desai N, Emmons E, Milner JD, Lee RJ, Wu CL, Sequist LV, Haas W, Ting DT, Toner M, Ramaswamy S, Maheswaran S, Haber DA
published in: Nature communications
information resource reference: Expression of ß-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun. 2017 02 09; 8:14344.
journal title abbreviation: Nat Commun
publication date: 2017-02-09T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 961046
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib.

Authorship 962075
type: Authorship
author rank in publication: 17
linked author: Sequist, Lecia
linked information resource: Expression of ß-globin by cancer cells promotes cell survival during blood-borne dissemination.

Authorship 964880
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib.

Authorship 964478
type: Authorship
author rank in publication: 1
linked author: Sequist, Lecia
linked information resource: Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC).

Authorship 964005
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer.

Authorship 966371
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged =65 Years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC.

Authorship 961021
type: Authorship
author rank in publication: 4
linked author: Sequist, Lecia
linked information resource: P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC.

Authorship 965169
type: Authorship
author rank in publication: 19
linked author: Sequist, Lecia
linked information resource: PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology.

Authorship 964012
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology.

Authorship 965712
type: Authorship
author rank in publication: 7
linked author: Sequist, Lecia
linked information resource: End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC).
PubMed Identifier: 27945488
author list: Sequist LV, Fidias P, Temel J, Kennedy BA, Ostler PA, Rabin MS, Huberman M, Keck J, Brown GL, Lynch TJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7275.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib.
PubMed Identifier: 27948816
author list: Costa DB, Cho BC, Sequist LV, Riely GJ, Halmos B, Kim J, Huberman MS, Pao W, Tenen DG, Kobayashi S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8105.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology.
PubMed Identifier: 27969529
author list: Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S309-S310.
journal title abbreviation: J Thorac Oncol
publication date: 2016-10-28T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology.
PubMed Identifier: 27969533
author list: Wakelee H, Goldman JW, Gadgeel S, Camidge DR, Reckamp KL, Ou SI, Yu HA, Solomon B, Liu SV, Pérol M, Dupuis NF, Nickel A, Karlovich C, Raponi M, Yurasov S, Litten J, Despain D, Soria JC, Sequist L, Carbone D
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S311-S312.
journal title abbreviation: J Thorac Oncol
publication date: 2016-10-28T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib.
PubMed Identifier: 27949020
author list: Jackman DM, Sequist LV, Cioffredi L, Ruiz MG, Janne PA, Giaccone G, Miller VA, Johnson BE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8035.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer.
PubMed Identifier: 27949112
author list: Enzinger PC, Ryan DP, Regan EM, Lehman N, Abrams TA, Hezel AF, Fidias P, Sequist LV, Blaszkowsky LS, Fuchs CS
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):4552.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.
PubMed Identifier: 27626514
author list: Bauman JR, Piotrowska Z, Muzikansky A, Gallagher E, Scribner E, Temel B, Sequist LV, Heist RS, Temel JS
published in: Journal of palliative medicine
information resource reference: End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. J Palliat Med. 2016 12; 19(12):1316-1319.
journal title abbreviation: J Palliat Med
publication date: 2016-09-14T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC.
PubMed Identifier: 27676531
author list: Barrios CH, Wu YL, Chih-Hsin Yang J, Sequist LV, Geater SL, Mok T, Hu CP, Yamamoto N, O'Byrne K, Lu S, Hirsh V, Sebastian M, Okamoto I, Shah R, Märten A, Massey D, Wind S, Schuler M
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct; 11(10S):S210-S211.
journal title abbreviation: J Thorac Oncol
publication date: 2016-09-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged =65 Years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC.
PubMed Identifier: 27676519
author list: Fein L, Wu YL, Sequist LV, Geater SL, Orlov S, Lee KH, Tsai CM, Kato T, Kiura K, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Mok T, Massey D, Märten A, Chih-Hsin Yang J
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged =65 Years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct; 11(10S):S202-S203.
journal title abbreviation: J Thorac Oncol
publication date: 2016-09-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 969317
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.
PubMed Identifier: 28202526
author list: Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H
published in: Cancer research
information resource reference: Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res. 2017 04 15; 77(8):2018-2028.
journal title abbreviation: Cancer Res
publication date: 2017-02-15T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
PubMed Identifier: 17671145
author list: Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4583-8.
journal title abbreviation: Clin Cancer Res
publication date: 2007-08-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.
PubMed Identifier: 23372014
author list: Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S
published in: Science (New York, N.Y.)
information resource reference: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013 Feb 01; 339(6119):580-4.
journal title abbreviation: Science
publication date: 2013-02-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
PubMed Identifier: 18981003
author list: Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7.
journal title abbreviation: Clin Cancer Res
publication date: 2008-11-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
PubMed Identifier: 19597022
author list: Pirl WF, Solis J, Greer J, Sequist L, Temel JS, Lynch TJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Epidermal growth factor receptor tyrosine kinase inhibitors and depression. J Clin Oncol. 2009 Aug 10; 27(23):e49-50; author reply e51.
journal title abbreviation: J Clin Oncol
publication date: 2009-07-13T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
PubMed Identifier: 16115901
author list: Sequist LV, Haber DA, Lynch TJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clin Cancer Res. 2005 Aug 15; 11(16):5668-70.
journal title abbreviation: Clin Cancer Res
publication date: 2005-08-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
PubMed Identifier: 21995391
author list: Lanuti M, Sequist LV, Sharma A, Mino-Kenudson M
published in: The New England journal of medicine
information resource reference: Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer. N Engl J Med. 2011 Oct 13; 365(15):1426-35.
journal title abbreviation: N Engl J Med
publication date: 2011-10-13T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.
PubMed Identifier: 22071650
author list: Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
journal title abbreviation: Ann Oncol
publication date: 2011-11-09T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
PubMed Identifier: 16857812
author list: Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
journal title abbreviation: Clin Cancer Res
publication date: 2006-07-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 985511
type: Authorship
author rank in publication: 2
linked author: Sequist, Lecia
linked information resource: AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.

AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.
PubMed Identifier: 28459327
author list: Vachani A, Sequist LV, Spira A
published in: American journal of respiratory and critical care medicine
information resource reference: AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. Am J Respir Crit Care Med. 2017 05 01; 195(9):1150-1160.
journal title abbreviation: Am J Respir Crit Care Med
publication date: 2017-05-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Detection of mutations in EGFR in circulating lung-cancer cells.
PubMed Identifier: 18596266
author list: Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA
published in: The New England journal of medicine
information resource reference: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008 Jul 24; 359(4):366-77.
journal title abbreviation: N Engl J Med
publication date: 2008-07-02T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 988015
type: Authorship
author rank in publication: 24
linked author: Sequist, Lecia
linked information resource: Scientific Advances in Thoracic Oncology 2016.

Authorship 986964
type: Authorship
author rank in publication: 20
linked author: Sequist, Lecia
linked information resource: Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.

Scientific Advances in Thoracic Oncology 2016.
PubMed Identifier: 28579481
author list: Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209.
journal title abbreviation: J Thorac Oncol
publication date: 2017-06-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.
PubMed Identifier: 28586967
author list: Piotrowska Z, Stirling K, Heist R, Campo M, Rizzo C, Digumarthy SR, Lanuti M, Fintelmann FJ, Lennes I, Farago A, Gainor J, Azzoli CG, Temel J, Mino-Kenudson M, Dias-Santagata D, Corcoran R, Shaw A, Engelman JA, Hata A, Sequist LV
published in: International journal of radiation oncology, biology, physics
information resource reference: Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220.
journal title abbreviation: Int J Radiat Oncol Biol Phys
publication date: 2017-05-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Non-small cell lung cancer in octogenarians: treatment practices and preferences.
PubMed Identifier: 17975495
author list: Oxnard GR, Fidias P, Muzikansky A, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol. 2007 Nov; 2(11):1029-35.
journal title abbreviation: J Thorac Oncol
publication date: 2007-11-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
PubMed Identifier: 22452895
author list: Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA
published in: The Lancet. Oncology
information resource reference: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May; 13(5):539-48.
journal title abbreviation: Lancet Oncol
publication date: 2012-03-26T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
PubMed Identifier: 22773810
author list: Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):E2127-33.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2012-07-06T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
author list: Sequist L, Fidas P, Temel J, Kolevska T, Rabin M, Boccia R, Burris H, Belt R, Kosmo M, Huberman M, Melnyk O, Guba S, Sleckman B, Klix M, Needles B, Mills G, Englund C, Caldwell D, Tesarowski D, Brown G, Edelman M, Lynch T.
published in: Proceedings of the 2007 Annual Meeting of the American Association for Cancer Research
information resource reference: Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Proceedings of the 2007 Annual Meeting of the American Association for Cancer Research. 2007; abstract 3521.
publication date: 2007-04-17T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

The effects of betamethasone and dexamethasone on blood pressure, heart rate, and heart rate variation in fetal sheep
author list: VanDam LM
published in: The effects of betamethasone and dexamethasone on blood pressure, heart rate, and heart rate variation in fetal sheep.
information resource reference: The effects of betamethasone and dexamethasone on blood pressure, heart rate, and heart rate variation in fetal sheep. 1995.
publication date: 1995-01-01T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 994421
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.

Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.
PubMed Identifier: 28692381
author list: Farago AF, Piotrowska Z, Sequist LV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma. J Clin Oncol. 2017 09 10; 35(26):2987-2988.
journal title abbreviation: J Clin Oncol
publication date: 2017-07-10T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.
PubMed Identifier: 18199725
author list: Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G
published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
information resource reference: A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):204-11.
journal title abbreviation: Cancer Epidemiol Biomarkers Prev
publication date: 2008-01-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.
PubMed Identifier: 18650517
author list: Sequist LV, Settleman JE, Ackman JB, Iafrate AJ
published in: The New England journal of medicine
information resource reference: Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung. N Engl J Med. 2008 Jul 24; 359(4):405-14.
journal title abbreviation: N Engl J Med
publication date: 2008-07-24T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Toward noninvasive genomic screening of lung cancer patients.
PubMed Identifier: 19414671
author list: Sequist LV, Engelman JA, Lynch TJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Toward noninvasive genomic screening of lung cancer patients. J Clin Oncol. 2009 Jun 01; 27(16):2589-91.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-04T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.
PubMed Identifier: 20676809
author list: Neal JW, Sequist LV
published in: Current treatment options in oncology
information resource reference: Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol. 2010 Jun; 11(1-2):36-44.
journal title abbreviation: Curr Treat Options Oncol
publication date: 2010-06-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
PubMed Identifier: 22277784
author list: Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA
published in: Science translational medicine
information resource reference: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 08; 4(120):120ra17.
journal title abbreviation: Sci Transl Med
publication date: 2012-01-25T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Protein degradation/chaperone system and histone deacetylase pathway.
PubMed Identifier: 19861924
author list: Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Protein degradation/chaperone system and histone deacetylase pathway. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1077-8.
journal title abbreviation: J Thorac Oncol
publication date: 2009-11-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
PubMed Identifier: 22145099
author list: Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA
published in: Cancer discovery
information resource reference: BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011 Sep; 1(4):352-65.
journal title abbreviation: Cancer Discov
publication date: 2011-07-22T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.
PubMed Identifier: 23552373
author list: Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M
published in: Science translational medicine
information resource reference: Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013 Apr 03; 5(179):179ra47.
journal title abbreviation: Sci Transl Med
publication date: 2013-04-03T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1002517
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study.

Authorship 1002862
type: Authorship
author rank in publication: 5
linked author: Sequist, Lecia
linked information resource: Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.
PubMed Identifier: 28751247
author list: Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017 10; 12(10):1588-1594.
journal title abbreviation: J Thorac Oncol
publication date: 2017-07-24T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study.
PubMed Identifier: 28712427
author list: Jacobs JM, Traeger L, Eusebio J, Simon NM, Sequist LV, Greer JA, Temel JS, Pirl WF
published in: Journal of psychosomatic research
information resource reference: Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study. J Psychosom Res. 2017 08; 99:28-33.
journal title abbreviation: J Psychosom Res
publication date: 2017-05-12T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

32 Fruit St.
type: Address
address line 1: Massachusetts General Hospital
address line 2: Yawkey Center Suite 7B
address line 3: 32 Fruit St.
city: Boston
postal code: 02114
state or province: MA

Authorship 1011291
type: Authorship
author rank in publication: 15
linked author: Sequist, Lecia
linked information resource: Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells.

Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells.
PubMed Identifier: 28883519
author list: Fachin F, Spuhler P, Martel-Foley JM, Edd JF, Barber TA, Walsh J, Karabacak M, Pai V, Yu M, Smith K, Hwang H, Yang J, Shah S, Yarmush R, Sequist LV, Stott SL, Maheswaran S, Haber DA, Kapur R, Toner M
published in: Scientific reports
information resource reference: Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. Sci Rep. 2017 09 07; 7(1):10936.
journal title abbreviation: Sci Rep
publication date: 2017-09-07T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment of advanced non-small cell lung cancer in the elderly.
PubMed Identifier: 16052430
author list: Sequist LV, Fidias P
published in: Seminars in respiratory and critical care medicine
information resource reference: Treatment of advanced non-small cell lung cancer in the elderly. Semin Respir Crit Care Med. 2005 Jun; 26(3):289-97.
journal title abbreviation: Semin Respir Crit Care Med
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1012413
type: Authorship
author rank in publication: 13
linked author: Sequist, Lecia
linked information resource: Microfluidic isolation of platelet-covered circulating tumor cells.

Microfluidic isolation of platelet-covered circulating tumor cells.
PubMed Identifier: 28932842
author list: Jiang X, Wong KHK, Khankhel AH, Zeinali M, Reategui E, Phillips MJ, Luo X, Aceto N, Fachin F, Hoang AN, Kim W, Jensen AE, Sequist LV, Maheswaran S, Haber DA, Stott SL, Toner M
published in: Lab on a chip
information resource reference: Microfluidic isolation of platelet-covered circulating tumor cells. Lab Chip. 2017 10 11; 17(20):3498-3503.
journal title abbreviation: Lab Chip
publication date: 2017-10-11T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.
PubMed Identifier: 19247082
author list: Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol. 2009 Mar; 4(3):281-3.
journal title abbreviation: J Thorac Oncol
publication date: 2009-03-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
PubMed Identifier: 20975380
author list: Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010 Nov; 5(11):1855-8.
journal title abbreviation: J Thorac Oncol
publication date: 2010-11-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.
PubMed Identifier: 21030453
author list: Cadranel J, Zalcman G, Sequist L
published in: The European respiratory journal
information resource reference: Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. Eur Respir J. 2011 Jan; 37(1):183-93.
journal title abbreviation: Eur Respir J
publication date: 2010-10-28T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
PubMed Identifier: 29051323
author list: Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clin Cancer Res. 2018 01 01; 24(1):197-208.
journal title abbreviation: Clin Cancer Res
publication date: 2017-10-19T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
PubMed Identifier: 17290067
author list: Sequist LV, Bell DW, Lynch TJ, Haber DA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007 Feb 10; 25(5):587-95.
journal title abbreviation: J Clin Oncol
publication date: 2007-02-10T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!
PubMed Identifier: 12874267
author list: Sequist LV, Lynch TJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol. 2003 Sep 01; 21(17):3186-8.
journal title abbreviation: J Clin Oncol
publication date: 2003-07-21T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1020011
type: Authorship
author rank in publication: 26
linked author: Sequist, Lecia
linked information resource: Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.

Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.
PubMed Identifier: 19704338
author list: Sequist LV, Fidias P, Heist RS, Ostler P, Muzikansky A, Lynch TJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1170-3.
journal title abbreviation: J Thorac Oncol
publication date: 2009-09-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
PubMed Identifier: 21768463
author list: Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011 Aug 20; 29(24):3307-15.
journal title abbreviation: J Clin Oncol
publication date: 2011-07-18T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A new BATTLE in the evolving war on cancer.
PubMed Identifier: 22586313
author list: Sequist LV, Muzikansky A, Engelman JA
published in: Cancer discovery
information resource reference: A new BATTLE in the evolving war on cancer. Cancer Discov. 2011 Jun; 1(1):14-6.
journal title abbreviation: Cancer Discov
publication date: 2011-06-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Genetic changes in squamous cell lung cancer: a review.
PubMed Identifier: 22722794
author list: Heist RS, Sequist LV, Engelman JA
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012 May; 7(5):924-33.
journal title abbreviation: J Thorac Oncol
publication date: 2012-05-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1025845
type: Authorship
author rank in publication: 15
linked author: Sequist, Lecia
linked information resource: Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers.

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers.
PubMed Identifier: 29118262
author list: Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV
published in: Science translational medicine
information resource reference: Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers. Sci Transl Med. 2017 Nov 08; 9(415).
journal title abbreviation: Sci Transl Med
publication date: 2017-11-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
PubMed Identifier: 17405897
author list: Sequist LV
published in: The oncologist
information resource reference: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist. 2007 Mar; 12(3):325-30.
journal title abbreviation: Oncologist
publication date: 2007-03-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Isolation of rare circulating tumour cells in cancer patients by microchip technology.
PubMed Identifier: 18097410
author list: Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M
published in: Nature
information resource reference: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20; 450(7173):1235-9.
journal title abbreviation: Nature
publication date: 2007-12-20T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells.
PubMed Identifier: 29170510
author list: Wong KHK, Tessier SN, Miyamoto DT, Miller KL, Bookstaver LD, Carey TR, Stannard CJ, Thapar V, Tai EC, Vo KD, Emmons ES, Pleskow HM, Sandlin RD, Sequist LV, Ting DT, Haber DA, Maheswaran S, Stott SL, Toner M
published in: Nature communications
information resource reference: Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nat Commun. 2017 11 23; 8(1):1733.
journal title abbreviation: Nat Commun
publication date: 2017-11-23T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1028738
type: Authorship
author rank in publication: 14
linked author: Sequist, Lecia
linked information resource: Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells.

Authorship 1029284
type: Authorship
author rank in publication: 3
linked author: Sequist, Lecia
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/93621558

https://connects.catalyst.harvard.edu/Profiles/profile/93621558
PubMed Identifier: 29178024
author list: Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC
published in: The patient
information resource reference: Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient. 2018 02; 11(1):131-141.
journal title abbreviation: Patient
publication date: 2018-02-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
PubMed Identifier: 17716025
author list: Sequist LV, Lynch TJ
published in: Annual review of medicine
information resource reference: EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med. 2008; 59:429-42.
journal title abbreviation: Annu Rev Med
publication date: 2008-01-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
PubMed Identifier: 17591931
author list: Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ
published in: The Journal of molecular diagnostics : JMD
information resource reference: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007 Jul; 9(3):320-6.
journal title abbreviation: J Mol Diagn
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PubMed Identifier: 18520291
author list: Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12.
journal title abbreviation: J Thorac Oncol
publication date: 2008-06-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1031641
type: Authorship
author rank in publication: 8
linked author: Sequist, Lecia
linked information resource: Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Authorship 1031251
type: Authorship
author rank in publication: 20
linked author: Sequist, Lecia
linked information resource: Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Authorship 1030941
type: Authorship
author rank in publication: 18
linked author: Sequist, Lecia
linked information resource: The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Authorship 1032052
type: Authorship
author rank in publication: 12
linked author: Sequist, Lecia
linked information resource: Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
PubMed Identifier: 29216356
author list: Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2018 03 01; 29(3):700-706.
journal title abbreviation: Ann Oncol
publication date: 2018-03-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
PubMed Identifier: 29241554
author list: Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH
published in: Cell reports
information resource reference: Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Rep. 2017 Dec 12; 21(11):3298-3309.
journal title abbreviation: Cell Rep
publication date: 2017-12-12T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
PubMed Identifier: 29217530
author list: Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047.
journal title abbreviation: Clin Cancer Res
publication date: 2017-12-07T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
PubMed Identifier: 29247830
author list: Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 04; 13(4):576-584.
journal title abbreviation: J Thorac Oncol
publication date: 2017-12-13T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
PubMed Identifier: 20479403
author list: Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jun 20; 28(18):3076-83.
journal title abbreviation: J Clin Oncol
publication date: 2010-05-17T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

FGFR1 amplification in squamous cell carcinoma of the lung.
PubMed Identifier: 23154548
author list: Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ
published in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
information resource reference: FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012 Dec; 7(12):1775-1780.
journal title abbreviation: J Thorac Oncol
publication date: 2012-12-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

ROS1-targeted therapy in non-small cell lung cancer.
PubMed Identifier: 23271356
author list: Sequist LV
published in: Clinical advances in hematology & oncology : H&O
information resource reference: ROS1-targeted therapy in non-small cell lung cancer. Clin Adv Hematol Oncol. 2012 Dec; 10(12):827-8.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2012-12-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1035932
type: Authorship
author rank in publication: 19
linked author: Sequist, Lecia
linked information resource: An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.

An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.
PubMed Identifier: 29301747
author list: Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S, Haber DA
published in: Cancer discovery
information resource reference: An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov. 2018 03; 8(3):288-303.
journal title abbreviation: Cancer Discov
publication date: 2018-01-04T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1037802
type: Authorship
author rank in publication: 11
linked author: Sequist, Lecia
linked information resource: Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles.

Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles.
PubMed Identifier: 29330365
author list: Reátegui E, van der Vos KE, Lai CP, Zeinali M, Atai NA, Aldikacti B, Floyd FP, H Khankhel A, Thapar V, Hochberg FH, Sequist LV, Nahed BV, S Carter B, Toner M, Balaj L, T Ting D, Breakefield XO, Stott SL
published in: Nature communications
information resource reference: Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nat Commun. 2018 01 12; 9(1):175.
journal title abbreviation: Nat Commun
publication date: 2018-01-12T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors.
PubMed Identifier: 20477469
author list: Pennell NA, Sequist LV
published in: Biomarkers in medicine
information resource reference: Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomark Med. 2007 Jun; 1(1):203-7.
journal title abbreviation: Biomark Med
publication date: 2007-06-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
PubMed Identifier: 21778168
author list: Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W
published in: The European respiratory journal
information resource reference: Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012 Feb; 39(2):366-72.
journal title abbreviation: Eur Respir J
publication date: 2011-07-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis.
PubMed Identifier: 22763454
author list: Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA
published in: Nature
information resource reference: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012 Jul 26; 487(7408):510-3.
journal title abbreviation: Nature
publication date: 2012-07-26T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
PubMed Identifier: 29376144
author list: Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF
published in: JCO precision oncology
information resource reference: Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018.
journal title abbreviation: JCO Precis Oncol
publication date: 2018-01-23T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer.
PubMed Identifier: 21807767
author list: Pirl WF, Traeger L, Greer JA, Bemis H, Gallagher E, Lennes I, Sequist L, Heist R, Temel JS
published in: The oncologist
information resource reference: Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. Oncologist. 2011; 16(9):1299-306.
journal title abbreviation: Oncologist
publication date: 2011-08-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1043942
type: Authorship
author rank in publication: 15
linked author: Sequist, Lecia
linked information resource: Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.